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B. Introduction 
1. Overview and aim of this study 
Ischemia reperfusion injury (IRI) is a serious clinical problem during liver 
resections, liver transplantation, and haemorrhagic shock. The 
pathomechanisms of this injury can be divided into incidents during ischemia 
and events occuring during reperfusion. Some main pathophysiologic features 
of ischemic liver cell injury comprise depletion of ATP, disturbance of natrium-
calcium homeostasis, and activation of phospholipase A2 (Bilzer and Gerbes, 
2000;Bilzer et al., 1994;Jaeschke et al., 1988). Reperfusion of livers leads to an 
aggravation of ischemic liver cell damage: reactive oxygen species (ROS) 
derived from activated Kupffer cells as well as the activation of proinflammatory, 
redox-sensitive transcription factors, such as NF-κB and AP-1, are discussed to 
contribute to hepatic reperfusion injury (Banafsche et al., 2001;Zwacka et al., 
1998;Fan et al., 1999). Numerous studies show beneficial effects of 
antioxidants like superoxide dismutase, katalase, glutathione, and N-
acetylcysteine on IRI (Bilzer et al., 1999;Serracino-Inglott et al., 2001;Mizoe et 
al., 1997b;Nagel et al., 1997). 
Among substances with known antioxidative properties, α-lipoic acid (LA), a 
compound established in the therapy of diabetic polyneuropathy (Coleman 
Michael D., 2001), is especially interesting: LA exhibits distinct regulatory action 
on signal transduction processes playing a central role in tissue damage and 
protection. In this context the potential of LA to regulate stress-related signalling 
pathways, such as NF-κB and AP-1 on the one hand (Saliou et al., 1999), and 
to activate cytoprotective protein kinases on the other hand, has recently been 
reported (Yaworsky et al., 2000;Maddux et al., 2001). 
α-lipoic acid is found naturally occuring as a prosthetic group in α-keto acid 
dehydrogenase complexes of mitochondria, and therefore plays a fundamental 
role in metabolism. Administration of LA to cells leads to a rapid uptake and 
reduction to dihydrolipoic acid (DHLA) (Han et al., 1997). LA and DHLA are both 
potent scavengers of ROS, such as hydroxyl radical, hypochlorous acid or 
singlet oxygen, as well as effective metal chelators forming complexes with e.g. 
Fe2+ (Biewenga et al., 1997;Packer et al., 1995). The low redox potential of the 
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LA/DHLA redox couple allows an increased de novo synthesis of GSH (Packer 
et al., 1995;Packer et al., 2001). 
Aim of this study 
The present study examined whether the administration of α-lipoic acid has 
protective potential in hepatic IRI. Special interest focussed on the 
characterization of mechanisms in LA-mediated hepatoprotection. Thereby, 
potential influence of LA on necrotic and apoptotic processes, hepatic redox 
state, energy metabolism, activation of proinflammatory transcription factors, 
and cytoprotective kinases was investigated. 
2. Hepatic ischemia reperfusion injury  
Hepatic ischemia reperfusion injury is a typical incident occuring during liver 
transplantation, liver resection, and hemorrhagic shock. It is characterized by 
reduced or completely missing blood supply accompanied by limited oxygen 
availability of the liver within a certain time period, called ischemia. This 
ischemic injury induces pathomechanisms which are aggravated by recovering 
blood flow during reperfusion, called reperfusion injury. Generally two forms of 
ischemic periods are distinguished: cold and warm ischemia. Cold ischemia 
occurs, when organs are prepared for transplantation. Thereby, organs are 
flushed with cooled storage solutions and subsequently stored at 4°C until 
transplantation. Warm ischemia especially occurs during liver resections, when 
blood supply is interrupted for surgery and the organ rests at body temperature. 
In transplantations warm ischemia happens during implantation of the organ. 
The following chapters describe the clinical impact of hepatic IRI and show main 
pathomechanisms of ischemia and reperfusion. 
2.1 Clinical relevance 
When Starzl and colleagues in 1963 (Starzl T.E., 1996) performed the first 
human liver transplantation they could not expect that the number of 
transplantations from former 12 per year would arise in the year 2000 to 
approximately 4500 only in the United States (Keeffe, 2001). 
Advances in immunosuppression and surgical technique made it possible that 
liver transplantation became a widely accepted therapy for children and adults 
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with end-stage liver disease (e.g. chronic hepatitis C, alcoholic liver disease, 
etc.). Nowadays, long-term survival rates (7 years) reach approximately 70%. 
Currently, a major problem is the limited availability of donor livers. Although the 
number of donors and liver transplants increased 2.4-fold from 1988 to 1997, 
the number of patients on the liver transplant list increased 15.6-fold and the 
number of waiting list deaths increased 5.8-fold over the same time period 
(Keeffe, 2001).  
Of those receiving livers, primary graft nonfunction leading to graft failure and 
retransplantation still occurs in 5-15% of patients. This represents the most 
common reason for retransplantation after immunological rejection (Lemasters 
and Thurman, 1997). Initial poor function of transplanted liver grafts occurs in 
10-25% of patients. The incidence of primary graft failure and initial poor 
function is strongly dependent on duration of warm ischemia and time of cold 
storage. Thus, the initial performance of the donor organ is strongly related to 
IRI associated with graft harvest, storage, and transplantation (Neuberger, 
2000;Lemasters and Thurman, 1997). 
This work especially concentrated on warm hepatic ischemia reperfusion injury, 
which appears during transplantation at the end of the surgery procedure 
implanting the organ, with the liver still lacking blood supply (Jaeschke, 1996). 
Warm ischemia and reperfusion injury also occurs during surgical liver 
resections, where parts of the liver are removed, while blood flow is interrupted 
by clamping supplying vessels, followed by resumption of normal blood flow. 
The complications arising from liver resection due to IRI are comparable in 
quantity and severity to that described for transplantation. Data from the 
“Klinikum der Universität München” Großhadern in 2000 (724 patients) show 
dysfunction of the liver in 14% and liver failure in 5% of all patients (Schauer R. 
2001, unpublished data).  
Due to the fact that the only effective treatment of primary liver failure is 
transplantation of the organ, it is of greatest clinical interest to reduce or even to 
prevent IRI.  
2.1.1 Ischemic injury 
A hallmark of ischemic liver injury represents ATP depletion due to lacking 
oxygen in the mitochondrial respiratory chain during anoxia. Physiological 
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consequence of this alteration in ATP availability is deterioration of energy 
dependent metabolic pathways and transport processes, leading to a massive 
imbalance of the intracellular ion status (Jaeschke, 1996). Thereby, cellular 
concentration of Na+ increases because of an inhibition of the Na+/K+-ATPase, 
directly connected to a rise in intracellular Ca2+-concentrations (Bilzer and 
Gerbes, 2000). The tremendous increase of intracellular Na+ is of greatest 
relevance for the development of cell swelling during ischemia, leading to 
cellular burst in the worst case. A central role in the pathogenesis of ischemic 
injury is also attributed to the increase of intracellular Ca2+ concentrations. As 
an essential consequence, activation of Ca2+ dependent proteases, 
phospholipases, and endonucleases were described leading to cell degradation 
processes and cell damage (Bilzer and Gerbes, 2000). Inflammatory incidents 
during ischemia are mediated via activation of phospholipase A2 (Bilzer et al., 
1994) resulting in prostaglandin and leukotriene formation.  
2.1.2 Reperfusion injury 
While reperfusion injury is not harmful following short periods of ischemia, it 
brings about the full expression of injuries induced by long periods of ischemia, 
e.g. warm ischemia > 30-45 min (Henderson, 1999). Reperfusion injury is a 
consequence and amplification of cell activation and damage developed during 
ischemia.  
Kupffer cell activation and reactive oxygen species 
Interest in mechanisms of reperfusion injury increased dramatically with the 
findings that xanthine oxidase- and mitochondria-derived reactive oxygen 
species (ROS) might be responsible for its pathophysiology. The initial, 
simplistic view was that these oxygen radicals generated during reperfusion 
cause cell damage by lipid peroxidation. However, more mechanistic studies 
characterizing the role of reactive oxygen-mediated liver injury showed that no 
relevant intracellular oxidant stress could be detected in the reperfused liver 
either in vitro or in vivo (Kobayashi et al., 1992;Jaeschke et al., 1988;Jaeschke 
and Farhood, 1991;Jaeschke, 1998). The extent of lipid peroxidation necessary 
to cause significant liver cell damage is by far higher than that ever measured 
during reperfusion (Jaeschke, 1998). The lack of intrahepatocellular reactive 
oxygen formation under pathophysiologically relevant conditions has directed 
interest towards oxidant stress in the hepatic vasculature. Especially Kupffer 
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cells (KC), but also neutrophils were identified as the critical sources of ROS 
during the initial phase of reperfusion injury (Rauen et al., 1994;Bilzer and 
Gerbes, 2000;Jaeschke, 1998;Lichtman and Lemasters, 1999;Serracino-Inglott 
et al., 2001). KC can be activated by subjecting them to hypoxia with 
subsequent reoxygenation. Activated KC also induce a network of cytokines 
(e.g. TNF-α, interleukin-1, etc.), participating in sinusoidal accumulation of 
granulocytes and microcirculatory failure. Reducing the capacity of KC to 
produce ROS by gadolinium chloride or methyl palmitate effectively protected 
against reperfusion injury, suggesting an important role of vascular oxidant 
stress in its pathophysiology (Jaeschke and Farhood, 1991;Lichtman and 
Lemasters, 1999). Furthermore, a lot of antioxidant strategies including 
treatment with superoxide dismutase (Mizoe et al., 1997), catalase (Okuda et 
al., 1992), N-acetylcysteine (Dunne et al., 1994), vitamin E (Nagel et al., 1997), 
and glutathione (GSH) (Bilzer et al., 1999) have been shown to possess 
protective potential in hepatic IRI and therefore generate a causal link between 
ROS formation and IRI.  
Besides KC activation, sinusoidal endothelial cell death during early reperfusion 
represents an important pathophysiological feature of IRI (Lemasters and 
Thurman, 1997). Thereby, denudation of sinusoids occurs, leading to an 
enhanced susceptibility of hepatocytes to ROS and other inflammatory 
mediators aggravating tissue injury.  
In addition to directly cause cell death and tissue injury, ROS generated during 
IRI can affect these processes indirectly by activating redox-sensitive signalling 
pathways, such as the transcription factors nuclear factor (NF)-κB and activator 
protein (AP)-1, which in turn enhance proinflammatory gene expression 
(Bradham et al., 1997;Jaeschke, 1998;Zwacka et al., 1998;Bradham et al., 
1999;Yamada et al., 2000;Kiemer et al., 2000;Tsoulfas and Geller, 
2001;Ricciardi et al., 2000).  
The NF-κB transcription factor family consists of five different members, termed 
p50, p52, p65 (RelA), c-Rel, and RelB, which can form various homo-and 
heterodimers. NF-κB is normally sequestered in the cytoplasm by proteins of 
the IκB family including IκB-α, IκB-β, IκB-γ, and IκB-ε. The induced form of NF-
κB is predominantly a p50 and p65 heterodimer, which translocates to the 
nucleus upon activation. The most commonly studied pathway of NF-κB 
activation involves phosphorylation of IκB-α on serine residues 32 and 36 by 
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the IκB-kinase (IKK) complex (Arrigo, 1999). This leads to ubiquitination and 
degradation of IκB, which thereby unmasks a nuclear target sequence on the 
NF-κB molecule and results in the translocation of NF-κB from the cytoplasm to 
the nucleus as an active transcription factor. In the early phase of IRI, activation 
of the proinflammatory transcription factor NF-κB may trigger upregulation of 
cytokines, including TNF-α, interleukin-1, and adhesion molecules, such as 
ICAM-1, that can mediate the subsequent subacute, inflammatory response. 
Expression of inducible nitric oxide synthase (iNOS)-mRNA during IRI is 
initiated by NF-κB activation after 1 h of reperfusion (Fan et al., 1999;Tsoulfas 
and Geller, 2001). 
The AP-1 family is another group of redox-regulated transcription factors that 
has been shown to be involved in IRI. AP-1 is a collective term referring to 
numerous combinations of dimeric transcription factors composed of jun, fos or 
ATF (activating transcription factor) subunits that bind to the common DNA site, 
the AP-1-binding site. The AP-1 family consists of homo- and heterodimers of 
jun (v-jun, c-jun, junB, junD), fos (v-fos, c-fos, fosB, Fra1, Fra2) or activating 
transcription factor (ATF-2, ATF-3, B-ATF) proteins (Fan et al., 1999;Karin et 
al., 1997). Regulation of AP-1 activity occurs at two major levels: extracellular 
stimuli modulate both the expression and the activity of AP-1 proteins. The 
abundance of AP-1 proteins is most commonly regulated by controlling the 
transcription of their genes. c-jun and c-fos can also be regulated by modulation 
of their stability. In the case of c-jun, phosphorylation by c-jun N-terminal kinase 
(JNK) reduces its ubiquitination and hence its degradation. Phosphorylation of 
serines 63 and 73 of c-jun by JNK is moreover known to increase its 
transcriptional activity (Karin et al., 1997). 
The activation of both NF-κB and AP-1 during IRI has been described to lead to 
inflammatory liver cell damage (Ricciardi et al., 2000;Jaeschke, 2000;Fan et al., 
1999). Recent studies even showed the direct relation between reduction of IRI 
in a rat liver model and blockade of NF-κB activation by the use of NF-κB 
antisense oligonucleotides (Banafsche et al., 2001). 
2.1.3 Mechanism of cell death: Apoptosis or Necrosis? 
Irreversible cell damage during IRI leads to cell death. The question, whether 
apoptosis or necrosis prevails in IRI is controversially discussed (Kohli et al., 
1999;Miyoshi and Gores, 1998;Clavien et al., 2001;Yadav et al., 1999;Gujral et 
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al., 2001;Patel et al., 1999). Although recent reports suggest that necrosis might 
be predominent (Gujral et al., 2001;Redaelli et al., 2002), both types of cell 
death have to be considered.  
Liver cell death during IRI is triggered by a number of insults arising from the 
external environment or from within the cell. These insults may engage cell 
surface receptors with death domaines leading to a proteolytic cascade 
involving initiator and executioner caspases and an apoptotic demise. 
Alternatively, the insults may profoundly disrupt mitochondrial function and 
result in loss of homeostasis accompanied by activation of hydrolases and a 
necrotic cell death (Kaplowitz, 2000). The distinction between apoptosis and 
necrosis has become fluent recently by the recognition that the same stimuli 
can induce either form of cell death. Thereby, mitochondria play a key role: 
selective release of mediators, such as cytochrome c amplifies the apoptosis 
program and profound loss of mitochondrial function leads to necrosis (Leist 
and Jäättelä, 2001). ROS and NO thereby participate as initiating factors and 
modulators (Kaplowitz, 2000;Gabbita et al., 2000;Finkel, 2001). Cell death can 
be described based upon morphological features as apoptotic or necrotic.  
Apoptosis, a controlled unobstructive mechanism of ridding the organism of 
damaged or unneeded cells, appears as shrinkage, cytoplasmic and nuclear 
condensation and fragmentation without loss of plasma membrane integrity 
(Rust and Gores, 2000).  
During apoptosis, a final execution phase can be distinguished from an initiation 
phase. In the execution phase, caspases, a family of cysteine proteases 
(cysteinyl aspartate-specific proteases), degrade the cell by cleavage of key 
proteins specifically after aspartate residues (Miller, 1997). Caspases are 
present in the cytosol of most cells as zymogens and need to be activated by 
cleavage of the proenzyme by proteolytic steps.  
It is generally known that caspases are activated by other caspases. Certain 
caspases are called effector or downstream caspases (e.g. 3, 6, 7), because 
they cleave key substrates, leading to apoptotic cell death (Cohen, 
1997;Sartorius et al., 2001;Rust and Gores, 2000). 
When initial liver cell damage is too severe, cells are no longer able to control 
and perform the tightly regulated and also energy-dependent apoptotic 
processes. This means that necrotic cell death appears. Necrosis involves 
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swelling and loss of plasma membrane integrity leading to lysis. The rapid 
phagocytic removal of apoptotic cells and fragments minimizes inflammation 
(Jaeschke, 2002), whereas the release of cellular content in necrosis promotes 
secondary inflammation. The most important feature of necrosis is that 
numerous mitochondria within a cell collapse and ATP production therefore 
tremendously declines. In consequence, cells swell, losing their ability to 
maintain ion gradients and calcium-dependent, nonspecific hydrolases start the 
disintegration process, ending in cell lysis (Kaplowitz, 2000). 
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Figure 1: schematic illustration of the main pathomechanisms of hepatic IRI. Endothelial 
cell (EC), Kupffer cell (KC), granulocyte (GC), reactive oxygen species (ROS), nitric oxide (NO). 
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2.1.4 Therapeutic approaches 
Many strategies have been developed to reduce IRI. Established proceedings 
thereby represent the use of University of Wisconsin (UW)- and other solutions 
for cold storage of livers prepared for transplantation. As protective ingredients 
in the UW-solution, lactobionate and glutathione were identified. Lactobionate 
was shown to reduce cell swelling during organ storage, due to marked osmotic 
properties (Bilzer M., 1997). The underlying mechanism of protective GSH 
effects remain unclear, but an antioxidative action was suggested (Belzer et al., 
1990). Beyond that, the xanthine oxidase inhibitor allopurinol, the Ca2+-
antagonist nicardipine, and the protease-inhibitor glycine were shown to exert 
protective effects when added to storage solutions. 
Besides interventions during organ storage, pre- and postischemic 
pharmacological therapies and also surgical interventions have been 
investigated to reduce IRI. Among them are: treatment with antioxidants, e.g. 
GSH, superoxide dismutase, katalase, N-acetylcysteine, etc. (Dunne et al., 
1994;Jaeschke and Farhood, 1991;Okuda et al., 1992;Mizoe et al., 1997;Nagel 
et al., 1997;Clavien et al., 1992;Bilzer et al., 1999), use of the cardiovascular 
hormone atrial natriuretic peptide (ANP) (Bilzer et al., 1994;Gerbes et al., 
1998;Kiemer et al., 2000;Kiemer et al., 2002), and ischemic preconditioning.  
The term ischemic preconditioning was introduced in 1986 by Murry and co-
workers (Murry et al., 1986). In this classical study the authors referred to 
ischemic preconditioning as an adaption of the myocardium to ischemic stress 
induced by repetitive short periods of ischemia and reperfusion. Meanwhile, the 
finding of an intrinsic protective property of the myocardium has been confirmed 
for other organs. Several years after characterization of ischemic 
preconditioning in the heart its beneficial effects were recognized in hepatic IRI 
after both warm (Peralta et al., 1997) and cold ischemia (Arai et al., 1999;Yin et 
al., 1998). Ischemic preconditioning attenuated sinusoidal endothelial cell death 
and decreased ROS formation by Kupffer cells (Arai et al., 1999). The very 
promising results reducing IRI by ischemic preconditioning of organs lead to 
numerous studies about the underlying mechanisms. Besides affecting 
adenosine and early NO formation during reperfusion, especially kinases, such 
as p38 mitogen activated protein kinase (p38 MAPK) were described to mediate 
ischemic preconditioning (Iesalnieks et al., 2001;Abe et al., 2000;Maulik et al., 
1998;Ping and Murphy, 2000;Nakano et al., 2000;Ono and Han, 2000).  
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In this context, it has been reported that ischemic preconditioning activates p38 
MAPK and blocking its activation by simultaneous administration of specific p38 
MAPK inhibitors abrogated the effect of hepatic and cardiac ischemic 
preconditioning (Amersi et al., 2002;Cohen et al., 2000;Weinbrenner et al., 
1997;Ping and Murphy, 2000;Maulik et al., 1998;Abe et al., 2000) and hypoxic 
preconditioning of hepatocytes (Carini et al., 2001).  
Mitogen activated protein kinases (MAPK) are highly conserved 
serine/threonine kinases, which are activated in response to a wide variety of 
stimuli including growth factors and environmental stresses (e.g. ischemia and 
reperfusion). Three major MAPK family members have been extensively 
studied: extracellular signal-regulated kinases (ERK1 and ERK2), c-jun N-
terminal kinase (JNK1 and JNK2), and p38 MAPK. MAPK are activated by 
protein kinase cascades that contain at least two upstream kinases. Dual 
phosphorylation is necessary for each MAPK to become fully activated (Chen et 
al., 2001).  
Various stressors, such as ischemia and reperfusion, hypo-osmolarity, etc. 
activate the p38 MAPK cascade. MEK3 and MEK6 (MEK=MAP/ERK kinase, 
also known as MAP kinase kinases or MKKs) are thought to be the major 
upstream kinases responsible for p38 activation, whereas MEK3/6 themselves 
are phosphorylated by MEKK (MAP kinase kinase kinases). Downstream 
events of p38 MAPK comprise regulation of AP-1 activity by induction of c-fos 
and c-jun and the activation MAPKAP kinase-2, which in turn is able to 
phosphorylate heat shock protein 27 (Chen et al., 2001).  
Another kinase, Akt (protein kinase B), has been reported to possess 
cytoprotective potential and being involved in ischemic preconditioning of the rat 
heart (Tong et al., 2000). Thereby, a causal relation between Akt activation and 
reduction of IRI by ischemic preconditioning was described.  
The serine/threonine kinase Akt is regarded as a key mediator of the 
physiological effects of insulin, of several growth factors (e.g. platelet-derived 
growth factor), and plays a crucial role in protecting cells from apoptosis (Leslie 
et al., 2001). The main downstream targets of Akt represent glycogen synthase 
kinase, the pro-apoptotic BAD, and caspase-9. Furthermore, Akt has been 
found to stimulate glucose uptake, glucose transporter (GLUT)1, and GLUT4 
translocation. GLUT1/4 represent insulin responsive glucose transporter 
isoforms, which are translocated from intracellular compartments to the plasma 
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membrane in response to insulin. After different growth stimuli, such as insulin, 
epidermal growth factor, or nerve growth factor, etc. Akt becomes activated as 
follows: activated phosphatidylinositol-3-kinase (PI3-K) produces 
phosphatidylinositol (3, 4, 5) triphosphate (PIP3), which is necessary for Akt 
translocation from the cytosol to the plasma membrane. There, Akt becomes 
phosphorylated twice, at Thr308 by PIP3-dependent kinase (PDK)-1 and at Ser 
473 by PDK-2 (Downward, 1998;Chan et al., 1999). 
2.1.5 Experimental model 
To study hepatic ischemia reperfusion injury (IRI), several approaches and  
techniques have been established. In this work the isolated perfused rat liver 
system was applied. 
This system represents a commonly used tool for exploring the physiology and 
pathophysiology of the liver (Gores et al., 1986) and is widely used in 
transplantation research (Dahl S., 1997) due to the following advantages:  
The method allows without much special equipment to set up a competent and 
versatile system of liver perfusion, maintaining its metabolic capacity and 
sensitivity towards different stimuli, e.g. hormones, for experimental periods of 
2-5 hours (Ahmed et al., 2001;Dahl S., 1997). Its popularity is due to the fact 
that, in contrast to in vivo models, the isolated perfused rat liver allows repeated 
sampling of perfusate, permits easy exposure of the liver to different 
concentrations of test substances and is amenable to alterations in temperature 
that would not be workable in vivo. Furthermore and most importantly, 
examining molecular mechanisms of substances, experiments can be done 
independently from the influence of other organ systems, plasma constituents 
and neural-hormonal effects (Bilzer M., 1997) focussing on liver-specific 
mechanisms.  
In contrast to other in vitro models, such as primary hepatocytes or cell 
organelles, hepatic architecture, communication between different liver cells, 
and bile flow are preserved in the isolated perfused rat liver (Gores et al., 
1986;Ahmed et al., 2001;Dahl S., 1997).  
Therefore, the isolated perfused rat liver system represents a suitable model to 
evaluate possible modulatory or hepatoprotective properties of pharmacological 
and surgical interventions in IRI. 
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3. α-Lipoic acid 
3.1 History 
In 1937, Snell and collegues reported about a nutritional factor extracted from 
potatoes, which was required for the growth of Lactobacillus, this factor was 
dubbed the ”potatoe growth factor” (Snell E.E. et al., 1937). Later research 
described an “acetate replacing factor” and a “pyruvate oxidation factor” in yeast 
extracts. Snell and Broquist proposed in 1949 that all of these factors were 
probably the same compound. In 1951 Reed and co-workers purified pale 
yellow crystals of a compound called “α-lipoic acid” (Reed L.J. et al., 1951). α-
Lipoic acid is also known as 6,8-thioctic acid, 1,2-dithiolane-3-pentanoic acid, or 
1,2-dithiolane-3-valeric acid (Figure 2) and represents an eight-carbon disulfide 
containing a chiral carbon, therefore existing in two enantiomeric forms. The R-
enantiomer is the naturally occuring form, whereas synthetic α-lipoic acid is a 
1:1 racemic mixture of the S- and R-enantiomers. 
SS
H
COOH
*
 
Figure 2: α-lipoic acid. 
 
LA was initially classified as a vitamin after its isolation, but it was later found to 
be synthesized by plants, animals and humans (Carreau, 1979;Gueguen et al., 
2000). In a recent study a mouse cDNA was cloned, characterized and 
demonstrated that it encodes a lipoic acid synthase located in mitochondria 
(Morikawa et al., 2001). Although it is known that octanoic acid and a sulfur 
source are the precursors of LA, the complete way of its biosynthesis has not 
yet been elucidated, (Gueguen et al., 2000;White, 1980;Dupre et al., 1980). 
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3.2 Physiological functions 
3.2.1 α-Keto acid dehydrogenases 
As lipoamide, LA is covalently bound to the amino group of lysine residues and 
functions as a prosthetic group in the α-keto dehydrogenase complexes. This 
multienzyme complex is composed of multiple copies of three enzymes: the α-
keto acid (pyruvate, branched chain α-keto acid, or α-ketoglutarate) 
dehydrogenase or E1, the dihydrolipoyl acyltransferase or E2, and the 
dihydrolipoyl dehydrogenase or E3. These three enzymes catalyze five 
reactions that oxidatively decarboxylate their substrates. Lipoamide is involved 
as a moiety of E2 to which an acyl group is attached, transferring it from 
thiamine pyrophosphate (TPP) on E1 to coenzyme A (CoA) to produce acyl-
CoA. In the process lipoamide is reduced, with its disulfide linkage broken. E3 is 
the enzyme that reoxidizes the lipoamide for another round of catalysis using 
NAD+, which is converted to NADH (Figure 3) (Packer et al., 1997;Packer, 
1998). Lipoamide therefore plays a major role in energy delivering processes of 
carbon hydrate and protein catabolism by importing their degradation product 
acetyl-CoA in the citrate cycle. 
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Figure 3: role of LA in oxidative decarboxylation of α-keto acids. E1: α-keto acid 
dehydrogenase; E2: dihydrolipoyl acyltransferase; E3: dihydrolipoyl dehydrogenase. 
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3.2.2 Glycine cleavage system 
The glycine cleavage system is a multienzyme complex that is only located in 
the hepatic mitochondrial matrix, catalyzing the oxidation of glycine to CO2, and 
ammonia, forming NADH and 5,10-methylenetetrahydrofolate. Thereby, α-
lipoate is attached to a lysine in the so called H-protein and is involved in the 
transfer of the methylamine moiety formed after oxidative decarboxylation of 
glycine (Packer et al., 1997). Bound LA is again reduced during the transfer 
(see Figure 3) of the one-carbon group from the lipoyl residue of H-protein to 
tetrahydrofolate (Bustamante et al., 1998). 
3.3 Pharmacokinetiks of LA  
3.3.1 LA absorption 
After oral administration, LA is rapidly absorbed, reaching maximum plasma 
concentrations of approximately 2.4 µM (200 mg p.o.) and 7.3 µM (600 mg p.o.) 
after approximately 0.5-1 h in fasted persons (Breithaupt-Grogler et al., 
1999;Menke G., 1995;Preiß R. et al., 1996;Hermann R. et al., 1996;Gleiter et 
al., 1996). Bioavailability of LA is indicated as ca. 29%, but is also dependent on 
food uptake, i.e. ingestion results in decreased plasma values (Teichert et al., 
1998b;Gleiter et al., 1996). LA possesses a half-life period (t1/2) of 30 min 
(Teichert et al., 1998). 
Only one report exists in the literature about the particular kinetic of LA uptake 
in rat liver. This work describes that LA in lower concentrations (< 75 µM) is 
absorbed by a saturable and in higher LA concentrations by a nonsaturable 
kinetic. Therefore, it is concluded that LA uptake at low concentrations is 
carrier-mediated. At higher concentrations diffusion becomes the major pathway 
(Peinado et al., 1989). 
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3.3.2 LA metabolism 
3.3.2.1 Reduction of LA 
After being absorbed, exogenously applied LA enters the mitochondrial matrix, 
and dihydrolipoamide dehydrogenase (E3, see B.3.2) reduces LA to DHLA 
(Figure 4), using electrons from NADH (Haramaki et al., 1997;Handelman et al., 
1994).  
     
COOH
S S
H*
H H
 
Figure 4: dihydrolipoic acid. 
 
Surprisingly, reduction of LA was also observed in human erythrocytes, which 
lack mitochondria. In the erythrocyte system, it was found that glutathione 
reductase, which exists mainly in the cytosol, is responsible for this NADPH 
dependent LA reduction (Constantinescu et al., 1995). In rat liver, reduction 
occurs equally by glutathione reductase and by dihydrolipoamide 
dehydrogenase (Packer, 1998). In addition, it has recently been found that 
thioredoxin reductase, which catalyzes the NADPH-dependent reduction of 
thioredoxin, reduces LA more efficiently than dihydrolipoamide dehydrogenase. 
The biological significance of this pathway is as yet unknown, but it represents 
another route of LA reduction in tissues. 
3.3.2.2 β-Oxidation 
Another metabolic event of lipoic acid is the β-oxidation of its pentanoic acid 
side chain. After administration of [1,6-14C]-lipoate to rats, the following LA 
metabolites were identified in urine: bisnorlipoic acid, tetranorlipoic acid, β-
hydroxybisnorlipoic acid, β-ketolipoic acid, and β-ketobisnorlipoic acid (Figure 5) 
(Spence and McCormick, 1976). In human beings, the metabolism is only 
poorly documented. β-Oxidation products, especially bisnorlipoic acid, were 
also detected in human plasma. In urine, the main metabolite was S4,S6-
dimethylbisnorlipoic acid (Figure 5), indicating a further metabolizing step before 
metabolites are excreted into urine (Locher M. et al., 1998;Biewenga et al., 
1997). 
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Figure 5: main metabolites of LA. 
 
Very recent findings confirmed the mentioned S-methylation adducts of LA and 
even presented a new metabolite, the disulfoxide of S2,S4-bismethylmercapto-
butanoic acid, which was identified as the major metabolite in dogs (Figure 6) 
(Schupke et al., 2001). 
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Figure 6: major LA metabolite in dogs, the disulfoxide of S2,S4-bismethylmercapto-
butanoic acid. 
 
3.3.3 LA toxicity 
Acute toxicity of LA is very low and represents approx. 400 mg/kg after 
intravenous administration to rats (Hexal AG, 1998). 
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3.4 Therapeutic use in diabetic polyneuropathy 
Diabetic polyneuropathy represents a major health problem, as it is responsible 
for substancial morbidity, increased mortality, and impaired quality of life. Near-
normoglycaemia is now generally accepted as the primary approach to prevent 
diabetic polyneuropathy, but is not achievable in a considerable number of 
patients. The therapeutic efficacy and safety of LA in diabetic polyneuropathy 
has been intensely investigated. Thus far, 15 clinical trials have been completed 
using different study designs, durations of treatment, doses, sample sizes, and 
patient populations (Ziegler et al., 1999). Within this variety of clinical trials, 
those with beneficial effects of LA used doses of at least 600 mg per day. The 
following major conclusions can be drawn from the recent controlled clinical 
trials: 
1.) Short term treatment for 3 weeks using 600 mg i.v. per day reduced the 
chief symptoms of diabetic polyneuropathy (Ziegler et al., 1995). 
2.) Oral treatment for 4-7 months tends to reduce neuropathic deficits and 
improves cardiac autonomic neuropathy (Ziegler and Gries, 1997;Ziegler 
et al., 1999). 
3.) LA (1,200 mg p.o. for 4 weeks) lowered plasma glucose levels in patients 
with type II diabetes (Konrad et al., 1999). 
4.) Preliminary data over 2 years indicate possible long-term improvement in 
motor and sensory nerve conduction in the lower limbs (Reljanovic et al., 
1999). 
5.) Clinical and postmarketing surveillance studies have revealed a highly 
favourable safety profile of the drug (Coleman Michael D., 2001). 
6.) A pivotal long-term multicenter trial (NATHAN I study) of oral treatment 
with LA is being conducted in North America and Europe using a 
clinically meaningful and reliable primary outcome measure that 
combines clinical and neurophysiological assessment. 
Hyperglycaemia, microangiopathy, and excessive oxidant stress are recognized 
causes of nerve damage in diabetic states. Recently, some protective 
mechanisms of LA were suggested in this context.  
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Besides its antioxidant activity, described in detail in B.3.5, LA has been shown 
to be involved in signal transduction processes concerning glucose metabolism. 
First, LA was described to stimulate glucose uptake in different cells (e.g. 
adipocytes, muscle cells) in an insulin-like manner by rapid translocation of the 
glucose transporters (GLUT)1 and GLUT4 from an internal membrane fraction 
to the plasma membrane (Moini et al., 2002;Yaworsky et al., 2000;Rudich et al., 
1999). Thereby, enhanced phosphatidylinositol-3-kinase (PI3-K)- as well as Akt-
activity were suggested responsible for this LA effect. Konrad et al. (Konrad et 
al., 2001a) reported that also p38 MAPK is involved in insulin- and LA-
dependent stimulation of glucose uptake. This study also confirmed the unique 
pathway of LA and insulin in the increase of glucose uptake via GLUT4 
translocation, and showed a causal link to forced PI3-K- and Akt-activity. It was 
described that also p38 MAPK activity is increased by LA- and insulin-
treatment. Concerning the role of kinase activation, activated p38 MAPK was 
proposed to stimulate GLUT4 activation, but not GLUT4 translocation. The latter 
was suggested to be mediated by the PI3-K/Akt pathway. 
3.5 Further properties 
Away from its use in the therapy of diabetic disorders, exogenous administration 
of LA has been shown to exert other interesting effects in different 
pharmacological topics and models. This chapter will especially focus on 
described LA effects touching this work.  
3.5.1 ROS-scavenging capacity and metal chelation 
There is general agreement about the antioxidant properties of LA. Many, 
mostly in vitro studies show that LA scavenges hydroxyl radicals, hypochlorous 
acid, peroxynitrite, and singlet oxygen. It does not appear to scavenge 
hydrogen peroxide or superoxide radical and probably does not scavenge 
peroxyl radicals (Suzuki et al., 1991;Biewenga et al., 1997;Biewenga and Bast, 
1995;Packer et al., 1995;Packer and Tritschler, 1996;Packer, 1998). DHLA, the 
reduced form of LA, additionally catches superoxide radical. Metabolites of LA, 
such as bisnorlipoic acid, β-hydroxynorlipoic acid, and tetranorlipoic acid are 
also described exerting antioxidative properties (Biewenga et al., 1997). 
Besides its direct radical scavenging action LA may have an antioxidant effect 
in biological systems through transition metal chelation. Antioxidant activity 
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thereby is obtained when a complex is formed in which the metal is shielded 
and coordination sites for O2 are occupied. It has been found that LA forms 
stable complexes with Mn2+, Cu2+, Zn2+, and Fe2+, with the complex being 
almost entirely formed with the carboxylate group (Biewenga et al., 
1997;Packer, 1998). Furthermore, LA was described to reduce Cd2+-induced 
toxicity in isolated hepatocytes, although the authors speculated that the effect 
was due to the conversion of LA to DHLA, which was the true chelating agent 
(Packer et al., 1995). 
3.5.2 Influence of LA on GSH metabolism 
Increase in cellular GSH synthesis after LA administration has been reported for 
different cell lines, such as Jurkat T cells, human erythrocytes, glial cells, 
neuroblastoma cells, lymphocytes, and rat and mouse liver (Han et al., 
1995;Han et al., 1997;Busse et al., 1992;Arivazhagan et al., 2001). The most 
detailed findings concerning the mechanism of LA increasing de novo synthesis 
of GSH were suggested by Han et al. as follows:  
A prerequesite for the obtained result is the low redox potential of the DHLA/LA 
redox couple of -0.32 V, which is more negative than the potential of 
cysteine/cystine (-0.22 V). Therefore, DHLA is able to directly reduce cystine to 
cysteine, which is regarded as the limiting factor of glutathione synthesis (Lu, 
1999).  
Thus, after adding LA to the cells, it is quickly absorbed and reduced to DHLA 
by the enzyme systems already mentioned in B.3.3.2.1, which is released to the 
extracellular space. DHLA subsequently reduces cystine to cysteine, which is in 
turn taken up again by the cells 10-times faster than cystine, and is therefore 
immediately available for GSH synthesis (Figure 7). An important note is that 
simple reduction of present GSSG to GSH by DHLA could not explain the 
significant effects obtained, due to only small intracellular amounts of GSSG 
(Han et al., 1997). 
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Figure 7: modified illustration of transport and reducing systems involved in intracellular 
GSH synthesis and possible mechanism for its stimulation by exogenously added LA 
(Han et al., 1997). 
 
3.5.3 Inhibition of NF-κB 
There are several lines of evidence that ROS are involved in activation of NF-
κB (see B.2.1.2) (Arrigo, 1999;Tsoulfas and Geller, 2001). Many researchers 
have reported antioxidants, including 2-mercaptoethanol, GSH, vitamin C, L-
cysteine, DHLA, and LA to inhibit NF-κB activation (Saliou et al., 1999;Suzuki et 
al., 1992;Packer and Suzuki, 1993;Packer, 1998). Activation of NF-κB by 
antioxidants is interrupted by scavenging ROS, which represent the initiating 
stimulus for I-κB phosphorylation and therefore translocation of NF-κB into the 
nucleus (see B.2.1.2). 
3.5.4 Influence of LA on ATP metabolism 
LA was described to modulate the availability of energy equivalents in diabetic 
rat hearts (Strodter et al., 1995) and in rat heart mitochondria (Zimmer et al., 
1995). As possible mechanisms for this LA effect reduced ATPase activity (LA 
and DHLA) and an increase in ATP synthase activity (especially DHLA) were 
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suggested (Zimmer et al., 1991). 
3.5.5 Involvement of LA in liver diseases 
LA has been intensely investigated as a therapeutic agent in a number of 
conditions related to liver disease, including alcohol-induced damage, 
mushroom poisoning, Cd2+-intoxification, CCl4 poisoning, and hyperdynamic 
circulation in biliary cirrhosis (Cohen M.R. et al., 1971;Muller and Menzel, 
1990;Bludovska et al., 1999;Vancini B., 1959;Marley et al., 1999;Bustamante et 
al., 1998). Beyond the antioxidative properties of LA, however, few is known 
about potential cellular and molecular targets of LA in liver disease.  
In summary, the pharmacological profile of LA lead to the hypothesis that LA 
might protect from hepatic IRI. 
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C. Materials & Methods 
1. Materials  
1.1 Chemicals 
Racemic α-lipoic acid (LA) was a gift from ASTA Medica (Batch No. 9811071, 
purity: 100%, Frankfurt/Main, Germany). All other materials were purchased 
from either Sigma (Deisenhofen, Germany) or Merck (Darmstadt, Germany) 
and had the quality of “pro analysi”, if not stated otherwise. 
1.2 Animals 
Male Sprague-Dawley rats were purchased from Charles River (Sulzfeld, 
Germany) and housed in a temperature- and humidity-controlled room under a 
constant 12-hour light-dark cycle. All perfusions were performed with rats 
weighing 220-280 g, having free access to chow (Ssniff-Diet, Ssniff 
Spezialdiäten GmbH, Soest, Germany) and water up to the time of the 
experiments. The study was registered with the local animal welfare committee. 
2. Methods 
2.1 Isolated perfused rat liver system 
2.1.1 Procedure 
Rats were anaesthetized with Narcoren  (sodium pentobarbital, 50 mg/kg body 
weight, i.p., Merial GmbH, Hallbergmoos, Germany), 0.1 ml heparine-sodium 
(25000 I.U./5 ml, Braun-Melsungen AG, Melsungen) was injected into the vena 
femoralis to prevent blood clotting. After incision of the abdominal wall, vena 
portae was cannulated with a 14-gauge intravenous catheter and the liver was 
perfused at a constant flow rate of 2.6 - 3.4 ml x min-1 x (g liver)-1 (membrane 
pump: Prominent® beta/4). Then vena cava inferior was cannulated via the right 
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atrium and ligated above the right vena renalis. After cannulating the bile duct 
with polyethylene-10 tubing, the liver was dissected from the gastrointestinal 
tract to exclude any nerval interaction (“isolated perfused rat liver”).  
      
perfusate outlet
bile duct
vena portae
V. cava
inferior
right atrium
perfusate entry
liver
_
_
_
_
_
_
_ 0
10
20
perfusor
burette
carbogen
membrane
pump
bubble trap
carbogen
KH solution
37°C
oxygenator
 
Figure 8: isolated rat liver perfusion technique - modified schematic description of the 
system (Lindl T., 1994). 
 
In all experimental groups, livers were perfused with hemoglobin- and albumin-
free, Krebs-Henseleit (KH) solution (pH 7.4, 37°C) in a nonrecirculating fashion. 
The perfusion medium was warmed and gassed with Carbogen (95% O2 and 
5% CO2, Messer Griesheim GmbH, Krefeld, Germany) by a tube oxygenator. 
Substances were infused via perfusors® (Braun Melsungen AG, Melsungen, 
Germany) into the KH solution before entering a bubble trap on the way to the 
liver. Perfusate and bile were collected during perfusion, whereas perfusate was 
immediately cooled on ice. Bile ran directly into 1 ml tubes and was determined 
volumetrically every 5 min with a Hamilton® syringe as µl x min-1 x (g liver)-1 
(Hamilton Bonaduz AG, Bonaduz, Switzerland). Portal pressure was read from 
a burette, which served as hydrostatic column (Sies, 1978;Wolkoff et al., 1987). 
It was determined every 5 min throughout the whole perfusion time and was 
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expressed as cm water as described previously (Wolkoff et al., 1987;Gores et 
al., 1986;Bilzer et al., 1999;Bilzer et al., 1994).  
At the end of the perfusion the liver was dissected and measured pressure was 
subtracted from the pressure during reperfusion. A schematic description of the 
perfusion apparatus and the operative procedure is shown in Figure 8. 
Krebs-Henseleit solution (KH, pH 7.4): 
NaCl 118 mM 
KCl 4.8 mM 
KH2PO4 1.2 mM 
MgSO4 x 7 H2O 1.2 mM 
NaHCO3 25 mM 
CaCl2 x 2 H2O 1.5 mM 
The solution was prepared with dist. water. 
2.1.2 Continuous liver perfusion 
The perfusion model was established according to Bilzer (Bilzer M., 1997). In 
order to characterize base levels of the applied parameters, continuous 
perfusions were performed.  
In continuous liver perfusions, control livers were perfused with KH solution for 
120 min. In LA treated livers a stock solution of LA (1 mg/ml KH solution) was 
infused by a perfusor® at a constant flow rate of 3.7 ml/h to reach a final 
concentration of 10 µM LA in the perfusing KH solution.  
LA stock solution: 
10.0 mg LA were dissolved in 10.0 ml KH solution using an ultrasonic bath 
(∼ 15 min). The solution was prepared freshly each time due to photo 
instability of LA in aqeous solutions and filtered (0.2 µm) into perfusor® 
syringes (Braun Melsungen AG, Melsungen, Germany). 
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2.1.2.1 Experimental protocol 
120 min continuous perfusion (Co; n=5):
120 min continuous perfusion: continuous treatment with 10 µM LA (n=5)
LA
120‘ P
 
Figure 9: livers were perfused for 120 min in absence (Co) or presence of 10 µM LA, 
which was added continuously after a 10 min equilibration time of the perfusion system. 
2.1.3 Short time infusion of H2O2 
Continuous perfusions were performed with a short time infusion (15 min) of 
H2O2 with a final concentration in the KH medium of 500 µM (see Figure 10).  
H2O2 stock solution: 
1.0 ml of H2O2 was diluted with 65.0 ml of dist. water and filled into a 
perfusor® syringe (Braun Melsungen AG, Melsungen, Germany). 
2.1.3.1 Experimental protocol 
100 min perfusion: 15 min treatment with 500 µM H2O2 (Co; n=3)
30‘ P H2O2 55‘ P
100 min perfusion: 15 min treatment with 500 µM H2O2 + 10 or 50 µM LA (n=3)
LA LAH2O2  
Figure 10: livers were perfused for 100 min with KH solution in absence (Co) or presence 
of LA (10 or 50 µM), which was added continuously, starting 20 min prior to a 15 min 
lasting infusion of 500 µM H2O2 .  
 
2.1.4 Warm ischemia and reperfusion 
The following different treatment protocols were performed to study the 
influence of LA on IRI of the rat liver after 60 min of warm ischemia. 
Livers were perfused for 30 min with KH solution (Pre-I), then perfusion was 
stopped for 60 min keeping the livers at 37°C. This period of warm ischemia 
(WI) was followed by up to 90 min of reperfusion (R). Three different schemes 
administering LA (10, 50 or 100 µM) were distinguished: “Continuous 
application”, i.e. applying LA continuously starting 20 min prior to ischemia, 
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“preconditioning” by infusing LA only 20 min prior to ischemia and “postischemic 
treatment”, i.e. LA administration during the reperfusion period (see Figure 11).  
The role of PI-3 kinase in LA preconditioning was investigated by simultaneous 
application of the selective PI-3 kinase inhibitor wortmannin (WM 100 nM, 
Alexis Biochemicals, Grünberg, Germany).  
2.1.4.1 Experimental protocol 
    
Pre-I: 30‘ 60‘ WI (37°C) 45‘ 90‘ 
Control group (Co; n=5):
Preconditioning with 10, 50 or 100 µM LA (n=5, each):
Postischemic treatment with 10 or 50 µM LA (n=5, each):
Preconditioning with 50 µM LA ± 100 nM wortmannin (n=5, each):
liver samples
Reperfusion (R):
LA
LA±WM
LA
Continuous treatment with 10 or 50 µM LA (n=5, each):
LA LA
 
Figure 11: experimental protocol. Livers were perfused for 30 min (Pre-I). After 60 min of 
ischemia at 37°C (WI), livers were reperfused (R) for 45 or 90 min. Thereby, three different LA 
treatment protocols were distinguished: “continuous application”, i.e. administration of 10 or 50 
µM LA continuously starting 20 min prior to ischemia. “Preconditioning”, applying 10, 50 or 100 
µM LA 20 min prior to ischemia and “postischemic application”, by infusing 10 or 50 µM LA 
during reperfusion. In additional experiments, livers were perfused for 30 min in the presence or 
absence of 100 nM wortmannin (WM) with or without 50 µM LA, which were given 20 min prior 
to ischemia. After ischemia (WI, 60 min) livers were reperfused for 90 min. Liver samples were 
taken at the time points indicated by arrows. 
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WM stock solution: 
1 mg WM (Alexis Biochemicals, Grünberg, Germany) was dissolved in 1 
ml DMSO (100%) and aliquots were stored at -20°C until the day of the 
experiment. 50 µl of the aliquot were diluted with 11.62 ml of KH solution, 
resulting in a final DMSO concentration of lower than 0.5%. This stock 
solution was filled into a perfusor® syringe. 
2.1.5 Sample preparation 
2.1.5.1 Liver tissue 
At the end of perfusion livers were dissected, weighed in a wet state, and snap 
frozen in liquid nitrogen. After reducing the livers to small pieces in liquid 
nitrogen they were stored at -80°C until further analysis.  
2.1.5.2 Perfusate 
Perfusate samples were collected at different perfusion or reperfusion time 
points for immediate determination of lactate dehydrogenase (LDH) and purine 
nucleoside phosphorylase (PNP) activities or stored at -80°C for further 
examination. 
2.2 Determination of enzyme activities 
In a photometric enzyme activity assay the decrease or increase of an 
absorbing substance, i.e. change of absorbance versus time is recorded. The 
slope of the resulting curve is proportional to the enzyme activity, which is 
calculated out of these data.  
2.2.1 Lactate dehydrogenase (LDH) activity 
The principle of this assay is the LDH catalyzed conversion reaction of pyruvate 
to lactate. Thereby, NADH is oxidized to NAD+, resulting in a NADH decrease, 
which is measured photometrically (Lambda Bio 20 photometer, Perkin Elmer) 
according to Bergmeyer (Bergmeyer HU, 1974). For calculation of LDH activity 
the extinction coefficient of NADH was used (ε365 nm = 3.34 L x mmol-1 x cm-1). 
Enzyme activities are expressed as mU x min-1 x (g liver)-1. 
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2.2.1.1 Reaction 
Pyruvate + NADH
LDH
Lactate + NAD+  
 
Figure 12: LDH-catalyzed reaction of pyruvate to lactate. 
 
2.2.1.2 Solutions 
Phosphate buffer:  
K2HPO4 (8.74 g/L) and KH2PO4 (6.8 g/L) solutions were mixed until a pH of 7.5 
was reached. 66 mg of pyruvate per L buffer were added. 
 
NADH solution: 
10 mg of NADH-Na2 were dissolved in 1 ml of 0.5% of a NaHCO3 solution. 
2.2.1.3 Assay procedure 
The following solutions were pipetted into volume-reduced cuvettes (1.5 ml, 
PESKE, Aindling-Pichl, Germany). The measurement was started after a short 
equilibration time (∼ 30 s). Absorbance was monitored for 1 min at room 
temperature (RT). 
 Reference: Sample: 
Phosphate buffer: 1,000 µl  500 µl  
Perfusate: ---- 500 µl  
NADH solution: ---- 10 µl  
In cases of high LDH activity (e.g.: 2’ R) 1:10 dilutions of the perfusate with 
phosphate buffer were used. 
2.2.2 Purine nucleoside phosphorylase (PNP) activity 
The principle of this assay is the PNP-catalyzed conversion reaction of inosine 
to hypoxanthine, coupled to a second enzyme, xanthine oxidase, converting 
hypoxanthine to uric acid. The resulting increase of uric acid was measured 
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photometrically according to Bergmeyer (Bergmeyer HU, 1974). For calculation 
of PNP activity the extinction coefficient of uric acid was used (ε293 nm = 12.5 L x 
mmol-1 x cm-1). Enzyme activities are expressed as mU x min-1 x (g liver)-1. 
2.2.2.1 Reactions 
Inosine + phosphate Hypoxanthine + D-ribose-1-phosphate
Hypoxanthine Xanthine Uric acid
PNP
Xanthine-
Oxidase
Xanthine-
Oxidase  
Figure 13: PNP- and xanthine oxidase-catalyzed reaction of inosine to uric acid. 
 
2.2.2.2 Solutions 
Phosphate buffer: 
K2HPO4 (87.4 g/L) and KH2PO4 (68 g/L) solutions were mixed until a pH of 7.4 
was reached.  
Inosine solution: 
13.41 mg of inosine were dissolved in 10 ml dist. water. 
Xanthine oxidase (X-1875: 50 U/1.5 ml): 
Freshly prepared dilution of xanthine oxidase (final concentration: 0.2 U/ml) in 
phospate buffer (see above). 
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2.2.2.3 Assay procedure 
The following solutions were pipetted into cuvettes and mixed immediately. The 
measurement was started after a short equilibration time (30 s). Absorbance 
was monitored for 1 min at RT. 
 Reference: Sample: 
Phosphate buffer: 200 µl  200 µl  
Xanthine oxidase solution: 200 µl  200 µl  
KH solution: 1,400 µl  ---- 
Dist. water: 200 µl  ---- 
Perfusate: ---- 1,400 µl 
Inosine solution : ---- 200 µl 
In cases of high PNP activity (e.g.: 2’ R) 1:10 dilutions of the perfusate with 
phosphate buffer were used. 
2.2.3 Caspase-3-like activity in liver tissue 
The activity of caspase-3-like proteases was determined fluorimetrically using 
the artificial tetrapeptide substrate Ac-DEVD-AFC (amino acid sequence DEVD: 
asp-glu-val-asp), based on the reports of Thornberry et al. (Thornberry, 1994) 
and Hentze et al. (Hentze et al., 2000). Thereby, the fluorophor 7-amino-4-
trifluoromethylcoumarin (AFC) is liberated by caspase-3-like cleavage of the 
substrate after its aspartate residue, resulting in an increased fluorescence 
(Figure 14). Because other caspases, such as caspase-2 and -7 show similar 
substrate specificity, this assay does not exclusively detect caspase-3 activity 
and is therefore termed caspase-3-like activity. Nevertheless, caspase-3 is the 
predominant caspase out of the caspase-3-like proteases in the liver extract 
(Hengartner, 2000). 
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2.2.3.1 Reaction 
O O
F
FF
N
H
Ac-DEVD
caspase-3
Ac-DEVD +
O O
F
FF
NH2
 
Figure 14: liberation of AFC by caspase-3-cleavage of Ac-DEVD-AFC. 
 
2.2.3.2 Solutions 
Extraction buffer: 
HEPES pH 7.5 25 mM 
MgCl2 5 mM 
EGTA 1 mM 
Substrate buffer: 
Ac-DEVD-AFC 50 µM 
HEPES pH 7.5 50 mM 
Sucrose 1% (m/v) 
CHAPS 0.1% (m/v) 
DTT 10 mM 
 
2.2.3.3 Assay procedure 
Frozen liver tissue (∼ 100 mg) was homogenized in 900 µl of ice cold extraction 
buffer with a Potter (Braun Biotech). Homogenates were subsequently 
centrifuged for 15 min at 20,160 x g and 4°C. Supernatants were stored at         
-80°C until analysis. The assay was carried out in duplicates on microtiter plates 
(Greiner GmbH, Frickenhausen, Germany) by mixing 10 µl of the liver cell 
extract with 90 µl of substrate buffer. Extraction buffer served as blank. 
Generation of 7-amino-4-trifluoromethylcoumarin (AFC) was determined 
kinetically by fluorescence measurement using the fluorescence plate reader 
BMG Fluostar (SLT Labinstruments, Crailsheim, Germany). Excitation 
wavelength was 385 nm, emission wavelength 505 nm. Enzyme activity was 
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calculated using an external AFC standard curve. Control experiments 
confirmed that the activity was linear with time and with protein concentration 
under the conditions described above.  
2.2.3.4 Determination of protein concentration: Pierce-assay  
The Pierce-assay is based on the combination of the biuret reaction (proteins 
with Cu2+ in alkaline solution) with bicinchonic acid. The reaction results in a 
purple colored complex measured photometrically at λ = 562 nm. 
Solutions: 
Reagent A: Na2CO3, NaHCO3, BCA reagent, Na-tartrate in 0.2 M NaOH. 
Reagent B: 4% aqueous solution of CuSO4. 
50 parts of reagent A were mixed with 1 part of reagent B. 200 µl out of this 
solution were added to 10 µl of sample, incubated at 37°C for 30 min and 
measured photometrically at λ = 562 nm (SLT Spectra, SLT Labinstruments, 
Crailsheim, Germany). Protein content of cellular extracts was quantified using 
standard solutions of bovine serum albumin (BSA) from 0-2,000 µg/ml. 
2.3 Enzymatical measurement of ATP 
In substrate kinetics, enzyme reactions are used to determine the concentration 
of one specific substance in a mixture. During reaction, substrate (here: ATP) is 
converted into a photometrically measurable product (here: NADPH). 
The principle of this assay is the complete conversion of ATP in the sample via 
a two-stage enzyme reaction forming NADPH. The assay is terminated after 15 
min, when present amounts of ATP are completely consumed and a maximal 
NADPH concentration is reached (see Figure 16), i.e. no further increase of 
absorbance at the corresponding wavelength. Thereby, for each mol ATP, 1 
mol NADPH is generated. Quantification of the ATP levels was performed using 
the extinction coefficient of NADPH (ε365 nm = 3,500 L x mol-1 x cm-1) according 
to Bergmeyer (Bergmeyer HU, 1974).  
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2.3.1 Reactions 
Glucose + ATP Glucose-6-P + ADP
Hexokinase
Glucose-6-P + NADP+
Glucose-6-P-
dehydrogenase
6-P-gluconolactone + NADPH + H+
 
Figure 15: conversion reactions during ATP measurement. 
 
2.3.2 Solutions 
Triethanolamine (TEA)-HCl buffer (pH 7.5-7.6): 
4.65 g of triethanolamine-HCl were dissolved in approx. 200 ml of dist. water. 
11 ml of 1 M NaOH solution were added. The solution was subsequently 
replenished to 500 ml with dist. water. 
MgCl2-solution:  
0.81 g of MgCl2 were dissolved in 40 ml of dist. water. 
Glucose-solution: 
3.6 g of glucose were dissolved in 40 ml of dist. water. 
HClO4-solution (6% w/v): 
2.08 ml of HClO4-solution (70%) were diluted to 40 ml with dist. water. 
K2CO3-solution: 
28.8 g of K2CO3 were dissolved in dist. water. 
NADP+-solution: 
27 mg of Na2-NADP+ were dissolved in 3 ml of dist. water. 
Glucose-6-phosphate-dehydrogenase suspension (G-6-P-DH) (140 U/mg): 
Enzymatic suspension in 3.2 M ammonium sulfate (Roche Diagnostics GmbH, 
Mannheim, Germany). 
Hexokinase (HK) suspension (140 U/mg): 
Enzymatic suspension (450 U/mg) in 3.2 M ammonium sulfate (Roche 
Materials & Methods 
 39 
Diagnostics GmbH, Mannheim, Germany), therefore a 1:3.21 dilution of the 
purchased hexokinase solution was necessary. 
2.3.3 Sample preparation 
1.) 1,000 µl of the HClO4-solution were added to frozen liver pieces (approx. 
300 mg) and homogenized on ice with a Potter (Braun Melsungen AG, 
Melsungen, Germany) at 8.75 x g. 
2.) 5 min centrifugation of the homogenate at 20,160 x g and 4°C. 
3.) 500 µl of the supernatant were treated with 45 µl of the K2CO3-solution to 
reach a final pH of 7.4 (pH control). The neutralized solution was kept on 
ice for 10 min. 
4.) 5 min centrifugation of the precipitated KClO4 (20,160 x g, 4°C) and 
immediate analysis of the supernatant. 
2.3.4 Assay procedure 
The following solutions were pipetted into cuvettes in the mentioned order. An 
auto zero was carried out after adding the glucose-solution.  
 Reference: Sample: 
TEA buffer: 885 µl  885 µl  
NADP-solution: 50 µl  50 µl 
MgCl2-solution: 100 µl  100 µl  
Dist. H2O: 300 µl  ----  
G-6-P-DH suspension: 5 µl  5 µl  
Glucose-solution: 150 µl  150 µl 
Dist. H2O: 6.89 µl  6.89 µl  
HK suspension: 3.11 µl  3.11 µl  
Supernatant: ---- 300 µl 
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2.3.5 Typical measurement 
To calculate the values for ATP levels in rat liver, ∆A was read at the endpoint 
of the transformation reaction. 
∆A
 
Figure 16: typical curve for the enzymatic conversion of ATP attained from a liver 
sample. The graph shows absorbance of the cumulative NADPH formation with an endpoint 
after 15 min reaction time. 
 
2.3.6 Calibration curve 
To assure that the analysis is in a linear range for the ATP concentrations found 
in rat liver, calibration curves were performed with ATP standard solutions 
(0.05-1.0 mM). All values obtained for rat livers were inside this range. 
y = 0.5074x + 0.0291
R2 = 09999
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Figure 17: representative calibration curve with ATP standard substance, indicating the 
relevant range for ATP concentrations found in rat liver. 
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2.4 Analysis of LA and tetranorlipoic acid by HPLC 
The analysis of these data was was performed by ASTA Medica. Quantification 
of LA and its metabolite tetranorlipoic acid (TNLA) were carried out by 
Alexander Kraft (ASTA Medica, Frankfurt/Main, Germany). 
2.4.1 Sample preparation 
2.4.1.1 Liver tissue  
Liver tissue was homogenized with a Potter in 0.1 M Na2HPO4/EDTA 0.1 M, pH 
7.0. 100 µl of the homogenate were deproteinized with 200 µl acetonitrile and 
centrifuged (12,000 x g, 10 min, 4°C). 100 µl of the supernatant were injected 
on the column. 
2.4.1.2 Perfusate 
Perfusate was diluted (1:10, 1:100, 1:200, as necessary) with elution buffer 
(63% KH2PO4, pH 2.3 and 37% acetonitrile) and 100 µl were directly injected for 
measurement. 
2.4.2 Instruments and procedure 
LA and TNLA were separated by 1 ml/min isocratic elution (63% KH2PO4, pH 
2.3/37% acetonitrile) on a LiChrospher (RP-18) 5-µm column (4 x 250 mm; 
Merck/Hitachi, Darmstadt, Germany) at ambient temperature with a Hewlett 
Packard HPLC system (1100 series: bin pump G1312A, autosampler G1329A). 
Electrochemical detection was performed by ESA Coulochem II (Chelmsford, 
USA). 
2.5 Quantification of cysteine, glutathione, oxidized 
cysteine, and oxidized glutathione by HPLC 
2.5.1 General considerations 
Many methods have been described to determine thiols and disulfides in 
different biological materials. A common problem of existing methods is their 
inability to simultaneously quantify the reduced and oxidized forms of several 
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thiols. In addition, the system has to be sensitive enough to guarantee detection 
of very low amounts of thiols and their corresponding oxidation products in 
complex matrices, such as liver tissue.  
The present method is based on the derivatization of free thiols with the 
fluorescence dye monobromobimane. The method exploits the ability of NaBH4 
to reduce disulfides, of N-ethylmaleimide (NEM) to block free thiols, and of 
dimethyl sulfoxide (DMSO) to stabilize the reduction process. Therefore, the 
procedure fulfills the above mentioned criteria allowing quantification of thiols 
separately from disulfides, and in addition being very sensitive due to 
fluorescence detection. 
The underlying procedure was originally described for plasma samples by 
Svardal et al. (Svardal et al., 1990) and Mansoor et al. (Mansoor et al., 1992) 
and was modified for measurement of liver and perfusate samples.  
Chromatographic conditions were modified from that published by Newton et al. 
(Newton et al., 1981). 
2.5.2 Solutions 
Solution I: 
5-Sulfosalicylic acid 25 g 
Dithioerythritol (DTE) 3.856 mg 
Dist. H2O               ad 50 ml 
 
Solution II: 
DMSO 6.4 ml 
Dist. H2O 3.45 ml 
NaCl 29.8 mg 
HBr (48%) 157.5 µl 
 
Solution III: 
53 mg NaBH4 (1.4 M) were dissolved in 1 ml of 0.05 N NaOH (prepared freshly 
for each analysis). 
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Solution IV: 
1.27 ml N-ethylmorpholine (1.0 M) were mixed with 8.73 ml of dist. water. 
Solution V: 
5.42 mg monobromobimane (20 mM) were dissolved in 1 ml of acetonitrile 
(Merck, HPLC grade). 
Solution VI: 
15 mg N-ethylmaleimide (NEM, 120 mM) were dissolved in 1 ml of PBS. 
Solution VII: 
905.8 µl HClO4 solution (70%) were diluted to 10 ml with dist. water. 
Solution VIII: 
Solution I was diluted 1:10, i.e. final concentrations: 5-sulfosalicylic acid 5%, 
DTE 50 µM. 
2.5.3 HPLC conditions 
2.5.3.1 Elution solvents for HPLC: 
Solvent A: 10% methanol/0.25% acetic acid. 
Solvent B: 80% methanol/0.25% acetic acid. 
The aqueous solution was adjusted to pH 3.9 with NaOH before mixing with 
methanol. 
2.5.3.2 Chromatography 
Separation of labelled monobromobimane derivatives was carried out on a 
Merck/Hitachi HPLC system (pump L6200A, autosampler AS-2000A, 
fluorescence detector F1000). A LiChrospher 100 (RP-18) 5-µm column (4 x 
125 mm; Merck/Hitachi, Darmstadt, Germany) was used at 15°C and a flow rate 
of 1.2 ml/min. The elution profile was as follows: 0-10 min, 2-20% B, linear 
gradient; 10-13 min, 20-100% B, linear gradient; 13-18 min, 100% B, column 
regeneration; 18-19 min, 100-2% B, linear gradient; 19-25 min, 2% B, column 
equilibration for next injection. The excitation wavelength was 390 nm, emission 
wavelength 465 nm. 
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2.5.4 Sample preparation 
2.5.4.1 Liver tissue 
Liver samples were prepared according to Anderson et al. (Anderson, 1985).  
1.) Approximately 500 mg of frozen liver tissue were weighed exactly and 
5.0 ml of solution VIII were added immediately and homogenized on ice 
with a Potter at 1,250 rpm. 
2.) Homogenate was centrifuged for 5 min at 20,160 x g (4°C) and 
supernatant  was stored at -80°C until analysis. 
3.) After thawing on ice homogenate was centrifuged for 10 min at 20,160 x 
g (4°C). 
4.) A: For analysis of thiols, 180 µl of the supernatant and 20 µl of solution 
VIII were pipetted together. The solution was vortexed and derivatized as 
described under C.2.5.5.1. 
B: Analyzing disulfides seperately from thiols needed a further step. 
Thereby, to 180 µl of the solution (see 4. A), 20 µl of solution VI was 
added (reaction time: 1 min). In this step present thiols react with NEM to 
a stable product (Asensi et al., 1994;Akerboom and Sies, 1989). This 
procedure masks thiols, which therefore do not react in the later 
derivatization reaction and are not falsely quantified as disulfides (Figure 
20, Figure 22). Derivatization was performed after reduction of the 
disulfides as described under C.2.5.5.2. 
2.5.4.2 Perfusate 
A: Perfusate was thawed on ice, 20 µl of solution I were added to 180 µl 
perfusate. After vortexing, precipitated protein was centrifuged for 2 min 
at 20,160 x g and 4°C. The supernatant was derivatized as described 
under C.2.5.5.1. 
B: Analyzing disulfides, as already mentioned, to 180 µl of the 
supernatant (see A), 20 µl of solution VI were added (reaction time: 1 
min). Derivatization was performed after reduction of the disulfides as 
described under C.2.5.5.2. 
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2.5.5 Derivatization procedures and chromatograms 
For analysis of thiol or disulfide samples, the following derivatization procedures 
were distinguished: 
2.5.5.1 Thiols 
Derivatization procedure for thiols consisted of adjusting the pH value to 9.0 
with N-ethylmorpholine before adding the fluorescence label 
monobromobimane. Addition of solution I protected thiols from oxidation without 
reducing disulfides (Svardal et al., 1990). A representative chromatogram of 
labelled thiols is shown in Figure 19. 
Derivatization reaction: 
R-SH +
10‘, RT, pH 9.0
darkness
N
N
O O
CH3CH3
CH3R-S
N
N
O O
CH3CH3
CH3Br
+   HBr
 
R =
NH2
COOH  
NH2
HOOC
O
N
H
N
H
O
COOHR =
  
Figure 18: derivatization reaction of thiols (R-SH) with monobromobimane (Yang et al., 
1995). 
 
Procedure: 
30 µl of a thiol sample (see above) 
+ 30 µl of solution VIII 
+ 160 µl dist. H2O 
+ 50 µl solution IV (pH 9.0, pH control) 
+ 10 µl solution V (10 min reaction time) 
+ 20 µl solution VII 
The solution with the generated monobromobimane derivatives was 
for cysteine; 
for glutathione. 
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immediately filled in HPLC-vials (brown glass) and subsequently injected in the 
HPLC system. Injection volume for liver samples was 5 µl. For perfusate, 
different injection volumes were necessary: Pre-I: 30 µl; 2’ R: 5 µl; 10’ R: 20 µl; 
20’ R/50’ R/90’ R: 30 µl. 
Representative chromatogram of labelled thiols derived from liver tissue: 
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Figure 19: representative chromatogram of monobromobimane-labelled thiols derived 
from liver tissue. Retention time for CYS-derivative: 4.04 min and for GSH-derivative: 6.76 
min. 
 
2.5.5.2 Disulfides 
The derivatization procedure for mixed disulfides is much more sophisticated 
than that for thiols: Excess of NEM is immediately inactivated by addition of 
NaBH4, whereas thiols are not liberated from thiol-NEM adducts. The optimal 
amount of NaBH4 used (1.4 M) for the reduction of disulfides was titrated by 
Svardal et al. and confirmed by own experiments (data not shown). DMSO and 
NaCl (solution II) were utilized to increase yield of the reduction reaction 
(Svardal et al., 1990). 
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NEM-reaction: 
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Figure 20: masking reaction of thiols (R-SH) with N-ethylmaleimide (NEM). A 
representative chromatogram of NEM-masked thiols is shown in Figure 22. 
 
Reduction reaction: 
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Figure 21: reduction of mixed disulfides with NaBH4. 
 
Reduction with sodium borohydride liberates the thiols CYS, GSH, and XSH, 
whereas XSH represents substances like homocysteine, homoglutathione, 
cysteinylglycine, etc., as well as cysteine and glutathione themselves.  
Procedure: 
30 µl of a disulfide sample (see above) 
+ 30 µl of solution III 
+ 160 µl of solution II (10 min reaction time) 
+ 50 µl solution IV (pH 9.0, pH control) 
+ 10 µl solution V (10 min reaction time) 
+ 20 µl solution VII 
As described above, the solution with the monobromobimane adducts was 
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immediately transferred into HPLC-vials and injected in the HPLC system. 
Injection volume for liver samples was 10 µl. For perfusate, different injection 
volumes were necessary: Pre-I: 30 µl; 2’ R: 10 µl; 10’ R: 20 µl; 20’ R/50’ R/90’ 
R: 30 µl. Representative chromatogram of labelled disulfides after reduction is 
shown in Figure 22. 
Chromatogram of thiols after reaction with NEM and monobromobimane: 
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Figure 22: chromatogram of NEM-labelled thiols, demonstrating a quantitative NEM-
reaction within 1 min, completely protecting from monobromobimane-labelling, i.e. no 
peaks appear for CYS- and GSH-derivatives. 
 
Representative chromatogram of labelled disulfides after reduction derived from 
perfusate: 
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Figure 23: representative chromatogram of monobromobimane derivatives derived from 
perfusate after reduction of disulfides. 
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 Retention time for CYS-derivative: 4.21 min and for GSH-derivative: 7.01 min. 
 
2.5.6 Calibration curves 
The HPLC-system was calibrated by injecting different concentrations of 
standard solutions. Therefore, standard substances (CYS, GSH, Na-GSSG) 
were dissolved in dist. water, except cystine, which was dissolved in 42.5% 
H3PO4 first and then diluted with dist. water. Due to rapid autoxidation in 
solution, dilutions of cysteine and glutathione were permanently kept on ice and 
prepared directly before labelling with monobromobimane.  
Because of the complex constitution of mixed disulfides in biological material no 
exact standard substance does exist. Therefore, cystine and oxidized GSH 
(GSSG) were chosen to reflect conditions for typical disulfide reductions. 
Cystine and GSSG standard solutions were also treated with solution I as 
described for samples. Derivatization procedure for standards was equal to that 
described for samples (see above 2.5.5.1, 2.5.5.2).  
Calibration curves were performed once a week without switching off the HPLC-
system throughout the week. Further standard injections followed every 10th 
sample and were compared to the calibration curves. All of the values 
determined for liver and perfusate samples were in the linear range of the 
calibration curves. 
Representative calibration curves for each standard substance: 
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Figure 24: representative calibration curves for the standard substances cysteine and 
glutathione. 
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cystine       oxidized glutathione (Na-GSSG) 
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Figure 25: representative calibration curves for the standard substances cystine and 
oxidized glutathione (Na-GSSG). 
 
All values for thiols (CYS, GSH) in liver are expressed as µmol/g liver, in 
perfusate as nmol x min-1 x (g liver)-1. Values for mixed disulfides (CYSSX and 
GSSX) in liver are expressed as µmol cystine or GSSG/g liver, in perfusate as 
nmol cystine or GSSG x min-1 x (g liver)-1. 
2.6 Detection of transcription factors by EMSA 
The electrophoretic mobility shift assay (EMSA) provides a method for detecting 
DNA-binding proteins (Kiemer, 2002). This method can be used in the study of 
sequence-specific DNA-binding proteins such as transcription factors, e.g. 
nuclear factor κB (NF-κB) and activator protein 1 (AP-1). The assay is based on 
the observation that complexes of protein and DNA migrate through a non-
denaturating polyacrylamide gel more slowly than free oligonucleotides.  
The gel shift assay was performed by incubating nuclear cell extracts with 32P 
end-labelled consensus oligonucleotides of NF-κB and AP-1. The shift between 
free and protein bound oligonucleotide appears after non-denaturating 
polyacrylamide gel electrophoresis. The specificity of the DNA-binding protein 
for the putative binding site was established by competition experiments using 
non-radioactive consensus oligonucleotides or other unrelated DNA sequences, 
e.g. AP-2 (data not shown). 
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2.6.1 Solutions 
Buffer A: 
HEPES (pH 7.9) 10 mM 
KCl 10 mM 
EDTA 0.1 mM 
EGTA 0.1 mM 
H2O dist.               ad 50 ml 
  
DTT 1 mM and 
PMSF 0.5 mM were added immediately before use. 
 
Buffer B: 
HEPES (pH 7.9) 20 mM 
NaCl 0.4 mM 
EDTA 1 mM 
EGTA 1 mM 
Glycerol 25% (v/v) 
H2O dist.               ad 50 ml 
  
DTT 1 mM and 
PMSF 0.5 mM were added immediately before use. 
 
STE buffer: 
NaCl 100 mM 
Tris-HCl (pH 8.0) 10 mM 
EDTA 1 mM 
prepared in dist. H2O.  
2.6.2 Preparation of nuclear extracts 
Preparation of nuclear extracts is achieved by swelling the cells first, adding a 
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hypotonic buffer and lysing the cells with Nonidet P-40, a nonionic detergens. 
Extraction of nuclear proteins from nuclei is achieved by the addition of 
hypertonic buffer. 
2.6.2.1 Procedure 
Nuclear extracts were prepared from frozen liver sections using a modification 
of the method described by Dignam et al. (Dignam et al., 1983). Thereby, tissue 
samples were homogenized in 3 ml of ice-cold hypotonic buffer A with a Potter 
at 1,250 rpm. The homogenate was transferred to a polypropylene centrifuge 
tube and after a 10 min incubation on ice, centrifuged at 1,000 x g for 10 min at 
4°C. The cell pellet was suspended in 1.4 ml of ice-cold buffer A. 90 µl of a 10% 
solution of Nonidet P-40 were added followed by 10 sec of vigorous vortexing. 
The suspension was incubated on ice for 10 min and then centrifuged at 12,000 
x g for 45 sec at 4°C. The supernatant was removed and the nuclear pellet was 
extracted with 200 µl of hypertonic buffer B by shaking for 30 min at 4°C. The 
extract was centrifuged at 12,000 x g for 10 min at 4°C and the supernatant was 
aliquoted (20 µl) and frozen at -80°C. After a 1:100 dilution with dist. water, 
protein concentration of the nuclear extracts was determined by the Lowry-
assay (see 2.6.3). 
2.6.3 Determination of protein concentration: Lowry-assay 
Protein content of the nuclear extract was determined photometrically according 
to the method of Lowry (Lowry OH, 1951). In this method the biuret reaction is 
combined with the Folin-Ciocalteau-phenol reagent resulting in a higher 
sensitivity of the colorimetric assay. 
2.6.3.1 Solutions 
Reagent A: 
10 g Na2CO3 were dissolved in 500 ml of 0.1 M NaOH. 
Reagent B: 
0.5 g K/Na-tartrate and 0.25 g CuSO4 were dissolved in 50 ml of dist. water. 
Solution 1: 
50 ml of reagent A were mixed with 1 ml of reagent B. 
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Solution 2: 
50 ml of Folin-Ciocalteu’s phenol reagent plus were diluted with 50 ml of dist. 
water.  
2.6.3.2 Procedure 
Protein solution was diluted with dist. water as described in 2.6.2.1. 200 µl of 
the sample were mixed with 1 ml of solution 1. After a 10 min incubation time at 
RT, 100 µl of solution 2 were added, vortexed, and incubated for at least 30 min 
in the dark. Absorbance was measured photometrically at 500 nm (Lambda Bio 
20 photometer, Perkin Elmer GmbH, Überlingen, Germany). Calculation of 
protein concentration was performed by creating calibration curves using bovine 
serum albumine in aqueos dilutions from 0-100 µg/ml. 
2.6.4 Radioactive labelling of oligonucleotides 
Radioactive labelling of oligonucleotides was attained by using the enzyme T4 
polynucleotide kinase (Promega, Heidelberg, Germany), which catalyzes the 
transfer of the terminal phosphate of ATP to the 5’ hydroxyl termini of 
polynucleotides. 
2.6.4.1 Used oligonucleotides 
The two following double-stranded oligonucleotide probes containing a 
consensus binding-sequence for either  
NF-κB: 5'-AGT TGA GGG GAC TTT CCC AGG C-3' or  
AP-1: 5'-CGC TTG ATG AGT CAG CCG GAA-3' (1.75 pmol/µl Promega, 
Heidelberg, Germany) were used.  
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2.6.4.2 Labelling procedure 
The following constituents were pipetted together on ice and incubated for 10 
min at 37°C.  
Oligonucleotide (1.75 pmol/µl) 2 µl 
T4 polynucleotide kinase buffer 1 µl 
[γ-32P]ATP (3000 Ci/mmol, 10 mCi/ml ) 5 µl 
H2O (nuclease free) 1 µl 
T4 polynucleotide kinase  (5-10 U/µl) 1 µl 
The reaction was stopped by adding 1 µl of 0.5 M EDTA.  
Separation of non-incorporated [γ-32P]ATP (Amersham, Braunschweig, 
Germany) from labelled oligonucleotide was achieved by using a NucTrap® 
Column (NucTrap® Probe Purification Column, Stratagene Europe, Amsterdam, 
Netherlands). Thereby, the mixture was replenished to 70 µl with STE buffer 
and brought up onto a NucTrap® Column, which had been equilibrated before 
with 140 µl of STE buffer. The solution was pushed through the column. This 
process was repeated once again with 70 µl of STE buffer and once with air. 
Labelled oligonucleotide was found in the eluate. Labelling efficiency was 
measured with a β-counter LS 6500 (Beckman, Krefeld, Germany). 
2.6.5 DNA binding reaction and gel electrophoresis 
Binding reaction of transcription factors to the labelled oligonucleotides was 
performed in presence of the nucleic acid polymer poly (dI-dC), a double 
stranded, alternating copolymer, which is utilized to reduce nonspecific binding 
of proteins to the radiolabelled DNA fragment. Therefore, gels and 
electrophoresis buffers with low ionic strength were chosen and non-
denaturating conditions were necessary to avoid disaggregation of the 
complexes due to lability of protein-DNA interactions. In addition, an effect 
called “caging” occurs in the gel matrix, preventing dissociation of protein and 
DNA by the surrounding gel. 
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2.6.5.1 Solutions 
5x binding buffer: 
Glycerol (100%) 20% (v/v) 
MgCl2 0.5 mM 
EDTA 2.5 mM 
NaCl 250 mM 
Tris-HCl 50 mM 
H2O dist.                ad 50 ml 
DTT (dithiothreitol) was added prior to use (final concentration: 2.5 mM). 
10x TBE buffer: 
Tris-base 53.9 g 
Boric acid ~27.5 g (pH 8.3) 
EDTA-Na2 3.72 
H2O dist.                ad 500 ml 
Gel loading buffer: 
Tris-HCl (pH 7.5) 250 mM 
Bromphenol blue 0.2% 
Glycerol 40% 
Non-denaturating gel 4.5%: 
10 x TBE 1 ml 
PAA (30%) 3 ml 
Glycerol (100%) 500 µl 
H2O dist. 15.5 ml 
  
TEMED 10 µl 
APS 10% (m/v) 150 µl 
Gel was prepared using a 30% solution of polyacrylamide/0.8% bisacrylamide 
(Rotiphorese Gel 30, Carl Roth GmbH+Co, Karlsruhe, Germany). 
 
Materials & Methods 
 56 
Solution 3: 
DTT 1 M 1 ml 
5x binding buffer 450 µl 
Loading buffer 50 µl 
2.6.5.2 Procedure 
10 µg nuclear protein were incubated for 10 min at room temperature in a 14 µl 
reaction volume containing:  
H2O dist. x µl 
Poly(dI-dC) (2 µg/µl) 1 µl 
Solution 1 3 µl 
10 µg protein 10 µl – x  µl 
Then 1 µl of 5 x 104 cpm radiolabeled oligonucleotide probe was added and 
mixed thoroughly. 
Nucleoprotein-oligonucleotide complexes were resolved by electrophoresis in a 
4.5% non-denaturing polyacrylamide gel in 0.25x TBE buffer at 100 V. The gel 
was autoradiographed with an intensifying storage phosphor imaging screen at      
-80°C for up to 3h, depending on the radioactivity of the labelled oligonuclotide. 
Specificity of the DNA-protein complex was confirmed by competition with a 
100-fold excess of either unlabeled NF-κB or AP-1 cosensus sequence. Signal 
detection and quantification was performed by phosphorimaging (Cyclone 
Storage Phosphor Screen, Canberra-Packard GmbH, Dreieich, Germany). 
2.7 Western blot 
Quantification of phospho-p38 mitogen activated protein kinase (phospho-p38 
MAPK) and phospho-Akt quantitatively (= phospho-protein kinase B) was 
performed by Western blot analyses. In order to determine cytosolic as well as 
intracellularly bound proteins whole liver cell lysates were made. After aquiring 
protein concentration of the liver cell extracts, proteins were separated by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE), blottet on a 
polyvinylidenfluoride (PVDF) membrane and then protein bands were visualized 
by chemiluminescence after incubating with different antibodies. 
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2.7.1 Sample preparation 
Approx. 100 mg liver tissue was weighed and 1 ml of ice cold lysis buffer was 
added immediately. After centrifugation for 10 min at 20,160 x g and 4°C, 200 µl 
of the supernatant was diluted with 800 µl of lysis buffer. Protein content of the 
obtained liver cell extract was determined using the method of Lowry et al. 
(Lowry OH, 1951) (see also 2.6.3),  
2.7.1.1 Solutions 
Lysis buffer: 
EDTA 2 mM 
NaCl 137 mM 
Glycerol 10% 
Na4P2O7 x 10 H2O 2 mM 
Tris 20 mM 
Triton X-100 1% 
C3H7Na2O6P x H2O 20 mM 
NaF 10 mM 
Lysis buffer was supplemented with 2 mM Na3VO4 , 1 mM PMSF and with a 25-
fold stock solution of the protease inhibitor mix Complete® (final dilution: 1/25, 
Boehringer Mannheim, Mannheim, Germany). 
5x Sample buffer: 
3.125 M Tris-HCl pH 6.8 100 µl 
Glycerol 100% 500 µl 
SDS 20% 250 µl 
DTT 16% 125 µl 
Pyronin Y 5% 5 µl 
H2O demin. 20 µl 
 
2.7.2 SDS-polyacrylamide electrophoresis (SDS-PAGE) 
Separation of proteins was achieved by denaturating SDS-PAGE in a vertical 
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apparatus (Mini PROTEAN 3, BioRad Laboratories Ltd., Hertfortshire, England). 
Molecular weight standard (Cruz Marker SC2035, Santa Cruz Biotechnology, 
Heidelberg, Germany) was used in each experiment to assure detection of the 
demanded protein. 
2.7.2.1 Discontinuous Electrophoresis 
Discontinuous electrophoresis represents a two step electrophoresis with two 
different gels: resolving and stacking gel. The resolving gel with small pores (pH 
8.8) and the stacking gel (pH 6.8) with large pores. In the electrode buffer 
terminating ions with low mobilities (e.g. glycine, which has a low net charge at 
the pH value of the stacking gel), in the gel exclusively leading ions with high 
mobility (e.g. Cl-) are used.  
Entering the stacking gel first, protein zones become concentrated. Because of 
the large pores in the gel matrix, mobilities are dependent on the net charge, 
not on the size of the molecule. Reaching the resolving gel frictional resistance 
for proteins increases, resulting in a slower migration towards the anode, and 
becoming higher concentrated and fractioned. Cl- and glycine, unaffected by the 
gel matrix, generate a new front and move ahead of the proteins. 
2.7.2.2 Solutions 
Resolving gel 10%: 
PAA solution 30% 5 ml 
1.5 M Tris-HCl, pH 8.8 3.75 ml 
SDS 10% 0.15 ml 
H2O dist. 6.1 ml 
10 min of vacuum degassing  
TEMED 15 µl  
APS 75 µl 
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Stacking gel: 
PAA solution 30% 1.7 ml 
1.5 M Tris-HCl, pH 6.8 1 ml 
SDS 10% 0.10 ml 
H2O dist. 7.0 ml 
10 min of vacuum degassing  
TEMED 20 µl  
APS 100 µl 
Gels were prepared using a 30% solution of polyacrylamide/0.8% bisacrylamide 
(Rotiphorese Gel 30, Carl Roth GmbH+Co, Karlsruhe, Germany). 
Electrophoresis buffer: 
Tris 3 g 
Glycine 14.4 g 
SDS 1 g 
H2O                                     ad 1,000 ml 
2.7.2.3 Procedure 
First, the resolving gel was filled into the vertical gel cassette with an overlay of 
demin. water. After polymerisation, the aqueous phase was removed, stacking 
gel was added and slot formers were immediately put in (polymerisation time: at 
least 1 h at RT). 
Prior to electrophoresis protein samples were denatured and proteins were 
charged negatively by adding 5x sample buffer (4 parts of protein sample mixed 
with 1 part 5x sample buffer) and boiling for 5 min at 95°C. Samples (100 µg 
protein) and molecular weight standard were filled into the slots and were 
separated electrophoretically after being filled up to 30 µl with 1x sample buffer. 
Stacking was carried out at 100 V for 21 min. Proteins were resolved at 200 V 
for 36 min.  
2.7.3 Coomassie staining 
In order to control sample loading and blotting efficiency gels were stained with 
Coomassie blue.  
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2.7.3.1 Solutions 
Staining solution: 
Coomassie blue 0.3% 
Acetic acid (100%) 10% (v/v) 
Ethanol (96%) 45% (v/v) 
in demin. water  
Filtration of the solution.  
Destaining solution: 
Acetic acid (100%) 10% (v/v) 
Ethanol (96%) 30% (v/v) 
in demin. water  
2.7.3.2 Staining procedure 
To control consistent blotting, gels were stained for 30 min in Coomassie 
staining solution. Gels were then destained twice for 10 min with destaining 
solution and stored over night in demin. water.  
2.7.4 Protein transfer and immunological detection 
To quantify the proteins of interest they had to be immobilized and then 
visualized. Therefore, SDS-PAGE separated proteins were electroblotted from 
the gel onto a polyvinylidenfluoride (PVDF) membrane (Immobilon-P , 0.45 µm 
pore size, Millipore Corporation, Bedford, USA). Proteins were detected by a 
first specific antibody (overnight, 4°C) and a second immunoglobulin antibody 
binding to the heavy chain of the first antibody (1 h, RT). The second antibody 
was coupled to horseradish peroxidase, which catalyzes the 
chemiluminescence producing oxidation of luminol and H2O2. This light 
emission was enhanced and prolonged by a chemical enhancer (e.g. phenols in 
Renaissance® chemiluminescence reagent plus, NEN, Köln, Germany) and 
recorded by a Kodak image station (Eastman Kodak Company, Rocester,USA).  
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2.7.4.1 Solutions 
Anode buffer I: 
Tris 30 g 
Methanol 200 ml 
H2O demin. 800 ml 
Anode buffer II: 
Tris 3 g 
Methanol 200 ml 
H2O demin. 800 ml 
Cathode buffer: 
ε-amino-n-caproic acid 5.2 g 
Methanol 200 ml 
H2O demin. 800 ml 
TBS-T pH 8.0 (washing buffer): 
Tris 3 g 
NaCl 11.1 g 
Tween 20 2.0 ml 
H2O demin.                    ad 1000 ml 
Adjusting pH to 8.0  
2.7.4.2 Semidry blotting 
Proteins were transferred between two horizontal electrodes (Biometra fastblot 
B43, Göttingen, Germany) from the gel onto a PVDF-membrane using the semi-
dry blotting technique, which is fast and needs only a small volume of buffer 
(Kyhse-Andersen, 1984). Thereby, anions migrate at the same speed, so that a 
regular transfer takes place. 
2.7.4.2.1 Procedure 
The blotting membrane was cut to the size of the resolving gel and deposited in 
methanol, demin. water, and anode buffer II for 5 min each. On the anode a 
bubble free stack of soaked blotting papers was placed, consisting of 6 sheets 
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drenched in anode buffer I and 3 sheets in anode buffer II. Onto this stack the 
membrane and the gel were put onto and covered with 9 sheets of blotting 
paper soaked with cathode buffer. 
55 min of blotting was conducted at a current of 0.8 mA/cm2 blotting surface 
and 115 V (power supply: Consort E835, Merck, Darmstadt, Germany). Then 
the membrane was dried for 30 min at 80°C. To block free binding sites, the 
membrane was incubated in a 5% (m/v) solution of low fat milk powder (Blotto, 
BioRad Laboratories Ltd.) in TBS-T for at least 1 h at RT. 
2.7.4.3 Antibodies 
2.7.4.3.1 p38 MAPK 
For phospho-p38 MAPK Western blotting, a polyclonal rabbit phospho-p38 
MAPK antibody (Thr 180/Tyr 182, Cell signalling, Frankfurt/Main, Germany) was 
used as first antibody. The secondary antibody was a horseradish peroxidase 
(HRP) conjugated polyclonal anti-rabbit IgG antibody (Dianova, Hamburg, 
Germany).  
Reprobes of the blots were performed with a polyclonal rabbit total-p38 MAPK 
antibody (Cell signalling, Frankfurt/Main, Germany) in order to control loading 
differences. 
2.7.4.3.2 Akt 
For phospho-Akt Western blotting, a polyclonal rabbit phospho-Akt (Ser 473, 
Cell signalling, Frankfurt/Main, Germany) served as first antibody. The second 
antibody was a horseradish peroxidase (HRP) conjugated polyclonal anti-rabbit 
IgG antibody (Dianova, Hamburg, Germany). 
Reprobes of the blots were performed with a polyclonal rabbit total-Akt antibody 
(Cell signalling, Frankfurt/Main, Germany) in order to control loading 
differences. 
2.7.4.4 Immunological detection 
The primary antibodies were diluted 1:1,000 in 1% Blotto in TBS-T or with 5% 
bovine serum albumine (BSA, for phospho-p38 MAPK antibody). Then the 
membrane was incubated with the primary antibody overnight at 4°C by shaking 
gently. After 4 washing steps for 10 min with TBS-T, the secondary antibody 
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(1:10,000 dilution with 1% Blotto in TBS-T) was added to the membrane for 1 h 
at RT. After another 3 washing steps for 10 min, two detection solutions were 
mixed (1:1, Renaissance® Chemiluminescence Reagent Plus, NEN lifescience, 
Cologne, Germany) as described in the manufacturer’s manual. The membrane 
was then incubated with this mix for 1 min. Chemiluminescence detection and 
quantification was performed with a Kodak image station (Eastman Kodak 
Company, Rocester, USA). 
2.8 Cell culture 
Cell culture experiments were performed to study later IRI events as previously 
investigated, e.g. the inhibition of NF-κB target genes, such as iNOS and the 
corresponding NO output. 
2.8.1 Medium and supplements 
Since macrophages are known to develop tolerance to lipopolysaccharides 
(LPS) activation upon continuous exposure to endotoxin in the culture medium, 
low endotoxin containing media and supplements were used. The cell culture 
medium was Dulbecco’s Modified Essential Medium (DMEM; PAN, Aidenbach, 
Germany), with 4 mM of L-glutamine and 10% of heat inactivated Fetal Calf 
Serum (FCS, Gibco-BRL, Eggenstein, Germany) added prior to use. 
2.8.2 Cells 
The murine macrophage cell line RAW 264.7 (American Type Culture Collection 
ATCC, TIB 71, Rockville, USA) was cultivated in DMEM with phenol red and 
was passaged once or twice per week. For investigations the cells were diluted 
and 104 cells/200 µl were seeded into a 96 well plate und cultivated for 3 days 
until the experiment.  
2.8.3 Cultivation 
2.8.3.1 Incubation 
RAW 264.7 macrophages were cultivated in an incubator (Heracell, Heraeus, 
Kendro Laboratory Products, Munich, Germany) at 37°C and 5% CO2 in fully 
humidified air. The cells grew in an adherent monolayer in polystyrole flasks in 
Materials & Methods 
 64 
an area of 75 or 150 cm2 or in 96 well plates (PESKE, Aindling-Pichl, Germany). 
2.8.3.2 Passaging 
The cell culture was splitted and transferred into new flasks dependent on the 
growing velocity of the macrophages (once or twice per week). Thereby approx. 
5 ml of medium were added to the cell line and cells were detached from the 
bottom of the flask by knocking strongly. After counting, cells were diluted (1:5 
or 1:10) and passaged. Cells were used until the 20th passage. After that, fresh 
cells were taken from a liquid nitrogen store.  
2.8.3.3 Cell counting 
Determination of cell concentration was performed in a Neubauer counting 
chamber.  
2.8.3.4 Freezing 
The macrophages were stored in liquid nitrogen (-196°C). To avoid bursting of 
the cells during freezing dimethylsulfoxide (DMSO) was added to the medium. 
The freezing medium was sterile filtrated after mixing. 
Freezing medium: 
DMSO 10 ml 
FCS  20 ml 
Medium 70 ml 
2.8.3.5 Thawing 
Cells stored in cryo tubes were taken from the liquid nitrogen, thawed as fast as 
possible and transferred into a 75 cm2 cell culture flask. Medium was changed 
after 24 h to remove dead cells. 
2.9 Photometrical detection of nitrite production 
2.9.1 Treatment of cells 
Cells were treated with bacterial lipopolysaccharide (LPS, E. coli, serotype 
055:B5, 1 µg/ml) in the absence or presence of various concentrations of LA (5-
500 µg/ml). LA was first dissolved in ethanol and further diluted with medium. 
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Final ethanol concentrations on the cells were < 0.1% and shown not to affect 
LPS induced NO production. After 20 h of stimulation, the concentration of 
nitrite, a stable metabolite of NO, was measured in the culture supernatant by 
the Griess assay (Green et al., 1982). In a different set of experiments the NO 
donor sodium nitroprusside (SNP, 1 mg/ml) was added to the cells in the 
presence or absence of LA and nitrite accumulation was measured after 1.5, 
2.5, and 4.5 h. 
2.9.2 Griess-assay 
The stable NO-oxidation product nitrite can be determined photometrically after 
its reaction to an azo-dye (Green et al., 1982). Quantification of LPS-induced 
nitrite formation was carried out using a calibration curve of different nitrite 
concentrations in medium (0-100 µM). 
2.9.2.1 Solutions 
Sodium nitrite: 
The standard curve was performed with different concentrations of sodium 
nitrite dissolved in medium (0-100 µM). The calibration solutions were prepared 
freshly for each experiment and measured together with cell supernatants on 
the same 96 well plate. 
Griess-reagents: 
A: sulfanilamide 1% (m/v) in H3PO4 5% (v/v) 
B: naphthylethylenediamine 0.1% (m/v) in dist. H2O 
2.9.2.2 Procedure 
After 20 h of stimulation with LPS in absence or presence of LA, 100 µl of the 
cell supernatants were pipetted in triplicates on a 96 well plate. After addition of 
90 µl of the Griess-reagents A and B each, the absorption was measured at λ = 
550 nm on a SLT Spectra plate reader (SLT Labinstruments Deutschland 
GmbH, Germany) and converted into nitrite concentrations. 
2.10 Photometrical determination of cell viability 
In order to exclude toxic effects of LA and its metabolites cell viability had to be 
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examined. A parameter for cell viability is the mitochondrial respiratory activity, 
which was determined by the MTT-test. 
2.10.1 MTT-assay 
Mitochondrial reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT) to the corresponding formazan was determined as an indicator 
of cell viability (Mosmann, 1983). 
2.10.1.1 Solutions 
Phosphate buffered saline (PBS): 
Na2HPO4       1.48 g 
KH2PO4       0.43 g 
NaCl        7.20 g 
H2O dist. ad 1000 ml 
After adjusting the pH value to 7.4 the solution was autoclaved for 40 min. 
MTT-solution: 
5 mg MTT were dissolved in 1 ml PBS, sterile filtrated and stored at -20°C. 
2.10.1.2 Procedure 
After removing the supernatant for nitrite determination, the cells were 
incubated with MTT solution for 10 min at 37°C and solubilized 2 h in DMSO. 
The extent of formazan production was determined photometrically at 550 nm.  
2.11 Statistical analysis 
All data are expressed as the mean ± SEM (n=number of organs). Unless 
stated otherwise, all experiments were performed with n=5 organs per treatment 
group. Statistical significance between groups was determined with one sample 
or student’s t-test. A p value < 0.05 was considered statistically significant. 
Statistical analyses were performed with GraphPad Prism® (Version 3.02, 
GraphPad Software Inc., San Diego, USA). Statistical significance was divided 
as recommended by GraphPad Prism software as follows: *** represents p-
values < 0.001, ** represents p-values < 0.01, and * represents p-values < 0.05. 
Results 
 67 
D. Results 
1. Validation of the liver perfusion system 
Validation of the isolated perfused rat liver system was carried out according to 
Bilzer (Bilzer M., 1997) by undertaking continuous liver perfusions and 
perfusions with a short time infusion of H2O2 in the absence or presence of LA. 
1.1 Continuous liver perfusion 
Continuous perfusions were performed in order to describe basal levels of the 
employed parameters (hepatic enzyme release, portal pressure, and bile flow) 
and to determine, whether LA affects these parameters of liver cell viability and 
hepatic function (Gores et al., 1986;Bilzer M., 1997). 
1.1.1 No influence of LA application on LDH and PNP efflux 
The most common indicator of liver tissue damage is the cellular enzyme 
release. Measurement of intracellular enzymes, such as lactate dehydrogenase 
(LDH) and purine nucleoside phosphorylase (PNP) in the perfusate reflects 
integrity of cell membranes and therefore cell viability. Marked increase in their 
activities suggest cell damage leading to a release of these proteins from the 
cytosol (Bilzer M., 1997;Fiegen et al., 1997;Gores et al., 1986;Rao et al., 
1990;Jaeschke et al., 1988).  
In continuous perfusions LDH and PNP release increased slightly without 
affecting liver function and viability (Figure 26). Administration of 10 µM LA, 
beginning 10 min after canulation of the portal vein, showed no significant 
influence on LDH and PNP efflux rates (Figure 26).  
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Figure 26: LA application did not influence enzyme efflux. Livers were perfused for 120 min 
in the absence (Co) or presence of 10 µM LA, which was added continuously 10 min after 
canulating the portal vein. Analysis of LDH (panel A) and PNP (panel B) activity in perfusate 
was carried out at different perfusion time points as described in “Methods”. Data are expressed 
as enzyme activity in mU x min-1 x (g liver)-1 and show means ± SEM of n=5 experiments in 
each group. 
 
1.1.2 No influence of LA administration on portal pressure 
Portal pressure is a marker for hemodynamic disturbances in the liver.  
No significant difference in portal pressure was obtained by applying 10 µM LA 
after a 10 min equilibration time of the perfusion system.  
Results 
 69 
        
po
rta
l p
re
ss
ur
e
[c
m
 w
at
er
]
0 20 40 60 80 100 120
0
1
2
3
4
Co
10 µM LA
perfusion time [min]
po
rta
l p
re
ss
ur
e
[c
m
 w
at
er
]
 
Figure 27: LA application did not influence portal pressure. Livers were perfused for 120 
min in the absence (Co) or presence of 10 µM LA, which was added continuously 10 min after 
canulating the portal vein. Portal pressure was monitored throughout perfusion as described in 
“Methods”. Data are expressed as cm water and represent means ± SEM of n=5 experiments in 
each group. 
1.1.3 No influence of LA application on bile flow 
Bile flow is an indicator of liver function (Fiegen et al., 1997;Gores et al., 
1986;Yin et al., 1998;Settaf et al., 2000;Bilzer et al., 1999;Bilzer et al., 1994) . 
Administration of 10 µM LA, continuously applied after a 10 min equilibration 
time significantly increased bile flow at some specific perfusion time points 
(Figure 28). 
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Figure 28: LA application enhanced bile excretion.  
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Livers were perfused for 120 min in the absence (Co) or presence of 10 µM LA, which was 
added continuously 10 min after canulating the portal vein. Bile flow was determined collecting 
bile every 5 min as described in “Methods”. Data are expressed as µl x min-1 x (g liver)-1 and 
represent means ± SEM of n=5 experiments in each group.  
2. Short time infusion of H2O2 
ROS production is well described to occur during reperfusion after hepatic 
ischemia. As preliminary experiments approaching ischemia and reperfusion 
studies, perfusions were performed with a short time infusion of H2O2, which is 
known as a typical member of oxygen radicals during reperfusion (Bilzer and 
Gerbes, 2000;Rauen et al., 1994;Jaeschke and Farhood, 1991;Okuda et al., 
1992).  
As a model of ROS production, perfusions with short time infusion of H2O2 
should elucidate, whether the antioxidant LA is able to reduce H2O2-induced 
liver cell injury. 
2.1 No influence of LA application on LDH and PNP 
efflux 
Continuous addition of LA (10 or 50 µM) 10 min after canulating the portal vein 
did not influence the increased enzyme release of livers stressed by a short 
time infusion of 500 µM H2O2 (Figure 29). 
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Figure 29: influence of LA application on enzyme efflux after infusion of H2O2. Livers were 
perfused for 100 min in the absence (Co) or presence of LA (10 or 50 µM), which was added 
continuously 10 min after canulating portal vein. After 30 min of perfusion, 500 µM H2O2 was 
infused for 15 min. Analysis of LDH (panel A) and PNP (panel B) activity in perfusate was 
carried out at different perfusion time points as described in “Methods”. Data are expressed as 
enzyme activity in mU x min-1 x (g liver)-1 and show means ± SEM of n=3 experiments in each 
group.  
 
2.2 No influence of LA administration on portal 
pressure 
Application of LA (10 or 50 µM), starting 10 min after canulating portal vein, 
significantly increased the already enhanced portal pressure at specific time 
points after infusion of H2O2 (Figure 30). 
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Figure 30: influence of LA application on portal pressure after infusion of H2O2. Livers 
were perfused for 100 min in the absence (Co) or presence of LA (10 or 50 µM), which was 
added continuously 10 min after canulating portal vein. After 30 min of perfusion, 500 µM H2O2 
was infused for 15 min. Portal pressure was monitored throughout perfusion as described in 
“Methods”. Data are expressed as cm water and represent means ± SEM of n=3 experiments in 
each group. *(#) p<0.05 represent significant differences in the values between untreated and 
50 µM (10 µM) LA treated livers. 
 
2.3 No influence of LA application on bile flow 
LA (10 or 50 µM), added continuously 10 min after canulating portal vein, did 
not significantly alter the H2O2 induced decrease of bile flow (Figure 31). 
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Figure 31: influence of LA application on bile flow after infusion of H2O2.  
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Livers were perfused for 100 min in the absence (Co) or presence of LA (10 or 50 µM), which 
was added continuously 10 min after canulating portal vein. After 30 min of perfusion 500 µM 
H2O2 was infused for 15 min. Bile was collected every 5 min as described in “Methods”. Data 
are expressed as µl x min-1 x (g liver)-1 and represent means ± SEM of n=3 experiments in each 
group. 
 
3. LA reduces IRI of the rat liver 
3.1 LA attenuates postischemic sinusoidal efflux of 
LDH and PNP 
In order to investigate an effect of LA on IRI, three different treatment protocols 
were employed, i.e. continuous, preischemic as well as postischemic 
administration of LA (Figure 11). Liver cell damage was determined again by 
measuring release of the cytosolic enzymes LDH and PNP into perfusate. 
Except for continuous application of LA, LDH and PNP efflux (Figure 32, Figure 
33, Figure 34) were significantly reduced in livers treated with 50 µM LA 
compared to untreated controls. By lowering the dose of LA to 10 µM only little 
effect on tissue protection could be seen. Raising the dose to 100 µM LA in the 
pretreatment protocol reduced enzyme release only in the initial reperfusion 
period. 
Comparison of the three treatment protocols showed that preconditioning with 
LA was the most efficient treatment protocol: enzyme release of livers 
preconditioned with LA was reduced almost throughout reperfusion. 
Postischemic and to an even lesser extent, continuous application of LA, 
reduced LDH and PNP release only at some specific time points during 
reperfusion. Thus, preconditioning with LA seems to be superior to its 
postischemic or continuous application. 
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3.1.1 Continuous LA administration 
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Figure 32: influence of continuous LA application on LDH- and PNP efflux. Livers were 
perfused for 30 min in the absence (Co) or presence of LA (10 or 50 µM), which was added 20 
min prior to ischemia and continuously after ischemia (60 min, 37°C) during 90 min of 
reperfusion. Analysis of LDH (panel A) and PNP (panel B) activity in perfusate was carried out 
at different reperfusion time points as described in “Methods”. Data are expressed as enzyme 
activity in mU x min-1 x (g liver)-1 and show means ± SEM of n=5 experiments in each group. # 
p<0.05 represents significant differences in the values between untreated and 10 µM LA treated 
livers.  
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3.1.2 Preconditioning with LA 
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Figure 33: influence of LA preconditioning on LDH- and PNP efflux. Livers were perfused 
for 30 min in the absence (Co) or presence of LA (10, 50 or 100 µM), which was added 20 min 
prior to ischemia (preconditioning). After 60 min of ischemia (WI, 37°C) livers were reperfused 
for up to 90 min. Analysis of LDH (panel A) and PNP (panel B) activity in perfusate was carried 
out at different reperfusion time points as described in “Methods”. Data are expressed as 
enzyme activity in mU x min-1 x (g liver)-1 and show means ± SEM of n=5 experiments in each 
group. *** p<0.001, ** p<0.01, and *(#), [+] p<0.05 represent significant differences in the values 
between untreated and 50 µM (10 µM) [100 µM] LA treated livers.  
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3.1.3 Postischemic LA application 
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Figure 34: influence of postischemic LA administration on LDH- and PNP efflux. Livers 
were perfused for 30 min. After ischemia (WI, 60 min, 37°C) livers were reperfused in the 
absence (Co) or presence of LA (10 or 50 µM, postischemic application). Analysis of LDH 
(panel A) and PNP (panel B) activity in perfusate was carried out at different reperfusion time 
points as described in “Methods”. Data are expressed as enzyme activity in mU x min-1 x (g 
liver)-1 and show means ± SEM of n=5 experiments in each group. ** p<0.01, and * p<0.05 
represent significant differences in the values between untreated and 50 µM LA treated livers.  
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3.2 LA preconditioning reduces portal pressure 
Portal pressure was strongly increased in the early reperfusion period and 
slightly but significantly reduced by preconditioning livers with 50 and 100 µM 
LA (Figure 36). Treatment with 10 µM LA, as well as postischemic and 
continuous administration of 50 µM LA did not affect portal pressure upon 
reperfusion (Figure 35,Figure 37). These findings underline that pretreatment 
with LA represents the most effective strategy attenuating IRI.  
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Figure 35: influence of continuous LA administration on portal pressure. Livers were 
perfused for 30 min in the absence (Co) or presence of LA (10 or 50 µM), which was added 20 
min prior to ischemia and continuously after ischemia (60 min, 37°C) during 90 min of 
reperfusion. Portal pressure was monitored throughout reperfusion as described in “Methods”. 
Data are expressed as cm water and represent means ± SEM of n=5 experiments in each 
group. 
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3.2.2 Preconditioning with LA 
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Figure 36: LA preconditioning reduces portal pressure. Livers were perfused for 30 min in 
the absence (Co) or presence of LA (10, 50, or 100 µM), which was added 20 min prior to 
ischemia. After 60 min of ischemia (WI, 37°C), livers were reperfused for up to 90 min. Portal 
pressure was monitored throughout reperfusion as described in “Methods”. Data are expressed 
as cm water and represent means ± SEM of n=5 experiments in each group. *** p<0.001, ** 
p<0.01, and * [+] p<0.05 represent significant differences in the values between untreated and 
50 µM [100 µM] LA treated livers. 
 
3.2.3 Postischemic LA application 
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Figure 37: influence of postischemic LA application on portal pressure.  
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Livers were perfused for 30 min. After ischemia (WI, 60 min, 37°C) livers were reperfused in the 
absence (Co) or presence of LA (10 or 50 µM, postischemic application). Portal pressure was 
monitored throughout reperfusion as described in “Methods”. Data are expressed as cm water 
and represent means ± SEM of n=5 experiments in each group. 
 
3.3 No significant influence of LA treatment on bile 
flow 
After 60 min of warm ischemia bile flow dramatically decreased during 
reperfusion to approx. 10% compared to preischemic levels. None of the 
treatment protocols and none of the different LA concentrations applied showed 
a significant increase of bile flow upon reperfusion. In some cases a tendency 
but no significance of an enhanced bile excretion was obtained (Figure 
38,Figure 39, Figure 40). 
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Figure 38: influence of continuous LA treatment on bile flow. Livers were perfused for 30 
min in the absence (Co) or presence of LA (10 or 50 µM), which was added 20 min prior to 
ischemia (60 min, 37°C) and continuously during reperfusion (90 min). Bile was collected every 
15 min during reperfusion as described in “Methods”. Data are expressed as µl x min-1 x (g 
liver)-1 and represent means ± SEM of n=5 experiments in each group.  
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3.3.2 Preconditioning with LA 
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Figure 39: influence of LA preconditioning on bile excretion. Livers were perfused for 30 
min in the absence (Co) or presence of LA (10, 50 or 100 µM), which was added 20 min prior to 
ischemia. After 60 min of ischemia (WI, 37°C), livers were reperfused for up to 90 min. Bile was 
collected every 15 min during reperfusion as described in “Methods”. Data are expressed as µl 
x min-1 x (g liver)-1 and represent means ± SEM of n=5 experiments in each group. 
 
3.3.3 Postischemic LA application 
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Figure 40: influence of postischemic LA administration on bile excretion. Livers were 
perfused for 30 min. After 60 min of ischemia (WI, 37°C) livers were reperfused in the absence 
(Co) or presence of LA (10 or 50 µM, postischemic application). Bile was collected every 15 min 
during reperfusion as described in “Methods”. Data are expressed as µl x min-1 x (g liver)-1 and 
represent means ± SEM of n=5 experiments in each group. 
 
The results so far provided evidence that LA is a potent inhibitor of IRI in rat 
livers and emerged that preconditioning livers with LA is more effective than 
postischemic or continuous treatment.  
Further investigations should now characterize the hepatoprotective action of 
Results 
 81 
LA. These mechanistic studies were undertaken by applying the most promising 
LA treatment scheme - the preconditioning protocol. 
3.4 LA metabolism during hepatic IRI 
Before examining the mechansisms of LA preconditioning amounts of LA in 
livers and perfusates were determined in order to know how much LA is 
responsible for the shown preconditioning effect. In terms of interpreting further 
results it was also necessary to get information about possible metabolites of 
LA and their quantity.  
Knowing the concentration of LA present in the different samples made it also 
possible to exclude any interaction with the applied assays. 
3.4.1 LA metabolites 
In the literature only little information is available about LA metabolites in rats. 
The publication of Spence et al. (Spence and McCormick, 1976) describes the 
identification of the following metabolites found in urine after intraperitoneal 
injection of LA: bisnorlipoic acid, β-hydroxybisnorlipoic acid, tetranorlipoic acid 
(TNLA), β-ketolipoic acid, and β-ketobisnorlipoic acid (see Figure 5). Peinado et 
al. (Peinado et al., 1989) report that 30% of the radioactivity (35S-labelled LA) 
administered to rat livers in a single-pass perfusion appear in liver tissue as 
metabolites of LA or LA itself (see also B.3.3.2). 
In this work only two of the above mentioned metabolites of LA were detected in 
quantifiable concentrations in liver as well as in perfusate: LA and TNLA. 
Therefore, presence of other known metabolites and presence of dihydrolipoic 
acid (DHLA) could be excluded by the analyses performed. 
In samples of untreated livers LA was not detectable. 
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3.4.2 LA and TNLA contents in liver after LA preconditioning 
The amounts of LA and TNLA in livers peaked after applying LA 20 min prior to 
ischemia reaching maximal values of 38.6 ± 7.9 nmol LA/g liver, which was 
equivalent to 1.21 ± 0.26% of total LA amount administered and 36.9 ± 8.9 nmol 
TNLA/g liver (Figure 41). LA and TNLA contents decreased continuously in the 
course of the experiment, i.e. Pre-I, after WI, and after 45 and 90 min of 
reperfusion. 
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Figure 41: LA and TNLA contents in liver after LA preconditioning. Livers were pretreated 
with 50 µM LA prior to ischemia (WI, 60 min, 37°C) followed by reperfusion for up to 90 min. LA 
and TNLA contents in liver were analyzed by HPLC (see “Methods”) after 30 min of perfusion 
(Pre-I), 60 min of WI, 45 and 90 min of reperfusion (R). LA and TNLA contents in liver are 
expressed as nmol/g liver and are shown as means ± SEM of n=3 organs in each group. In 
untreated livers LA was not detectable (n.d.). 
 
3.4.3 LA and TNLA contents in perfusate after LA pre- or 
postischemic treatment 
Direct intravenous administration of antioxidants during reperfusion has been 
described to reduce hepatic IRI (Bilzer et al., 1999). Therefore, LA and TNLA 
contents in perfusate were measured to describe the differences of LA 
preconditioning versus postischemic treatment concerning their antioxidative 
potential in the vasculature. Figure 42 shows that measurable amounts of LA 
and TNLA in perfusate were present before, during, and initially after ischemia 
of LA pretreated organs. After 10 min of reperfusion only traces of TNLA were 
detectable. As expected, postischemic LA treatment showed a continuous 
presence and higher concentrations of both LA and TNLA in perfusate during 
reperfusion. 
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Figure 42: LA and TNLA contents in perfusate after LA pre- and postischemic treatment. 
Livers were perfused for 30 min in the absence (Co) or presence of 50 µM LA, which was added 
either 20 min prior to ischemia (preconditioning) or given continuously after ischemia (60 min, 
37°C) during 90 min of reperfusion (postischemic application). LA and TNLA contents in 
perfusate were analyzed by HPLC (see “Methods”) at the time points indicated. LA and TNLA 
contents in liver are expressed as nmol/g liver and are shown as means ± SEM of n=3 organs in 
each group. In perfusates of untreated livers LA and TNLA were not detectable (n.d.). 
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4. Mechanisms of LA preconditioning 
In order to investigate the mechanisms of LA preconditioning, GSH metabolism 
was examined first. The facts that application of GSH has been shown to 
protect from IRI (Bilzer et al., 1999) and that LA has been described to increase 
GSH concentration in different cell types (Han et al., 1997) and in mouse and 
rat liver (Busse et al., 1992;Arivazhagan et al., 2001) lead to the hypothesis that 
the protective action of LA could be explained, at least in part, by increasing 
GSH. 
4.1 CYS and CYSSX contents in liver 
Due to reports in the literature stating (Han et al., 1997) that LA increases GSH 
synthesis by improving cystine utilization the following experiments should 
show, if this thesis is also true for the applied IRI model (see B.3). Han and 
collegues described that GSH synthesis is increased by LA and DHLA, 
restoring the cysteine pool of cells, which is known as the limitating factor in 
GSH synthesis. Figure 43 demonstrates that LA preconditioning did not 
significantly influence cysteine (CYS) as well as oxidized cysteine (CYSSX) 
levels in liver at any time point analyzed. 
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Figure 43: influence of LA pretreatment on cysteine (CYS) and oxidized cysteine (CYSSX) 
contents in liver.  
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Livers were perfused for 30 min in the absence (Co) or presence of 50 µM LA, which was added 
20 min prior to ischemia (Pre-I). After 60 min of ischemia (WI, 37°C), livers were reperfused (R) 
for up to 90 min. CYS and CYSSX contents in liver were determined by HPLC (see “Methods”) 
and are expressed as µmol/g liver. Data show means ± SEM of n=5 experiments.  
 
4.2 CYS and CYSSX contents in perfusate 
Also in perfusate cysteine concentrations remained unaltered by LA 
pretreatment compared to untreated control livers, whereas contents of oxidized 
cysteine in perfusate were significantly reduced during IRI (Figure 44). 
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Figure 44: influence of LA pretreatment on CYS and CYSSX contents in perfusate. Livers 
were perfused for 30 min in the absence (Co) or presence of 50 µM LA, which was added 20 
min prior to ischemia (Pre-I). After 60 min of ischemia (WI, 37°C), livers were reperfused (R) for 
up to 90 min. CYS and CYSSX contents in livers were determined by HPLC (see “Methods”) 
and are expressed as nmol x min-1 x (g liver)-1. Data show means ± SEM of n=5 experiments. ** 
p<0.01, * p<0.05 represent significant differences to untreated livers. 
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4.3 GSH and GSSX contents in liver 
Interestingly, in contrast to the findings in the literature (Han et al., 1997;Busse 
et al., 1992), LA pretreatment significantly decreased GSH concentrations in 
liver during ischemia (WI) compared to untreated controls (Figure 45). At every 
other time point GSH values in LA preconditioned organs did not significantly 
differ from untreated livers.  
Levels of oxidized GSH (GSSX) were significantly reduced by LA 
preconditioning in the preischemic period, whereas at each other time point 
GSSX concentrations were comparable to control organs (Figure 45).  
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Figure 45: influence of LA pretreatment on GSH and GSSX contents in liver. Livers were 
perfused for 30 min in the absence (Co) or presence of 50 µM LA, which was added 20 min 
prior to ischemia (Pre-I). After 60 min of ischemia (WI, 37°C), livers were reperfused (R) for up 
to 90 min. GSH and GSSX contents in liver were determined by HPLC (see “Methods”) and are 
expressed as µmol/g liver. Data show means ± SEM of n=5 experiments. *** p<0.001, * p<0.05 
represent significant differences to untreated livers. 
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4.4 GSH and GSSX contents in perfusate 
The amounts of GSH and GSSX found in perfusate of LA pretreated livers did 
not significantly differ from untreated controls at any time point analyzed (Figure 
46). 
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Figure 46: influence of LA pretreatment on GSH and GSSX contents in perfusate. Livers 
were perfused for 30 min in the absence (Co) or presence of 50 µM LA, which was added 20 
min prior to ischemia (Pre-I). After 60 min of ischemia (WI, 37°C), livers were reperfused (R) for 
up to 90 min. GSH and GSSX contents in perfusate were determined by HPLC (see “Methods”) 
and are expressed as nmol x min-1 x (g liver)-1. Data show means ± SEM of n=5 experiments. 
 
4.5 LA preconditioning reduces activation of NF-κB 
and AP-1  
It is well known that the redox-sensitive transcription factors NF-κB and AP-1 
are activated in IRI with the consequence of an increased expression of 
proinflammatory mediators (Tsoulfas and Geller, 2001;Fan et al., 
1999;Bradham et al., 1997;Yamada et al., 2000). Therefore, the effect of LA 
pretreatment on NF-κB and AP-1 activity was investigated. After 90 min of 
reperfusion NF-κB activation was significantly decreased in LA preconditioned 
livers (Figure 47, panel A), whereas activation at any earlier time point was not 
affected. AP-1 DNA binding activity was significantly reduced after WI and 90 
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min of reperfusion (Figure 47, panel B). 
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Figure 47: effect of LA preconditioning on postischemic NF-κB and AP-1 activation. 
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Livers were untreated (Co) or preconditioned with 50 µM LA 20 min prior to ischemia. After 60 
min of ischemia (WI), livers were reperfused for up to 90 min. Binding activity of nuclear protein 
to the radiolabeled consensus binding sequences of NF-κB (panel A) and AP-1 (panel B) were 
assessed by EMSA (see “Methods”) after WI, 45 and 90 min of reperfusion (R). Data show one 
representative gel shift experiment for each time point on the left side. Bars on the right side 
show densitometrical analysis of the shifts, whereby NF-κB/AP-1 activation of LA 
preconditioned livers is expressed as x-fold of the values in the correlating untreated group. 
Data is shown as means ± SEM of n=4 livers in each group, analyzed in two independent shifts. 
*** p<0.001, ** p<0.01 and * p<0.05 represent significant differences in the values between 
untreated and LA pretreated livers. 
 
4.6 Elevated ATP content in LA pretreated livers 
ATP content of livers is an indicator of their energetic status. As ATP depletion 
is a typical biochemical feature of ischemic periods (see B.2.1.1) it was 
interesting to see, whether LA administration influences this parameter. In the 
course of ischemia and reperfusion ATP content of livers significantly 
decreased (Figure 48). As shown in Figure 48, preconditioning with LA 
significantly increased ATP contents compared to control livers after WI and at 
the end of the reperfusion period. 
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Figure 48: effect of LA preconditioning on ATP content in liver. Livers were perfused in the 
absence (Co) or presence of 50 µM LA, which was added 20 min prior to ischemia (WI, 60 min, 
37°C), followed by reperfusion for up to 90 min. ATP content in liver was analyzed after 30 min 
of perfusion (Pre-I), after 60 min of warm ischemia (WI), and after 45 and 90 min of reperfusion 
(R) as described in “Methods”. Data are expressed as µmol/g liver and show means ± SEM of 
n=5 experiments. ** p<0.01 represents significant differences of the values between untreated 
and LA pretreated livers. 
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4.7 Phospho-p38 MAPK in IRI 
The role of p38 MAPK activation in IRI is controversially discussed (Abe et al., 
2000). There is evidence that ischemic and hypoxic preconditioning are 
mediated via the activation of p38 MAPK (Weinbrenner et al., 1997;Maulik et 
al., 1998;Nakano et al., 2000;Ping and Murphy, 2000;Carini et al., 2001).  
Before evaluating a possible influence of LA treatment, the activation pattern of 
p38 MAPK in this model of IRI was investigated. Figure 49 shows that 
phosphorylation of p38 MAPK slightly but significantly decreased during 
ischemia and reperfusion. 
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Figure 49: time course of p38 MAPK activation. Livers were perfused for 30 min with KH 
solution prior to ischemia (WI, 60 min, 37°C). Western blot analysis with antibodies against 
phosphorylated (phospho-p38) and total p38 MAPK (tot-p38) (see “Methods”) was performed 
after 30 min of perfusion (Pre-I), after 60 min of WI, and after 45 and 90 min of reperfusion. One 
representative Western blot is shown. Western blots were analyzed densitometrically, whereby 
p38 MAPK phosphorylation during ischemia and reperfusion was expressed as x-fold of the 
values in the preischemic group. Values are shown as means ± SEM of n=3 livers in each 
group, analyzed in two independent Western blots. ** p<0.01, * p<0.05 represent significant 
differences of the values between preischemic and postischemic untreated livers. 
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4.7.1 LA preconditioning does not affect activation of p38 
MAPK 
In order to investigate p38 MAPK as a crucial kinase in LA preconditioning we 
determined its activation compared to untreated organs. Pretreatment of livers 
with LA, however, exerted no significant effect on phosphorylation of p38 MAPK 
(Figure 50). Thus, p38 MAPK activation does not seem to be involved in LA 
preconditioning. 
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Figure 50: influence of LA preconditioning on p38 MAPK phosphorylation. Livers were 
perfused for 30 min in the absence (Co) or presence of 50 µM LA, which was added 20 min 
prior to ischemia (WI, 60 min, 37°C). Western blot analysis with antibodies against 
phosphorylated (phospho-p38) and total p38 MAPK (tot-p38) (see “Methods”) was performed 
after 30 min of perfusion (Pre-I) and after 60 min of WI. One representative Western blot is 
shown for each time point. Western blots were analyzed densitometrically, whereby p38 MAPK 
phosphorylation in LA preconditioned livers was expressed as x-fold of the values in the 
untreated group. Values are shown as means ± SEM of n=5 livers in each group, analyzed in 
two independent Western blots. 
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4.8 Phospho-Akt in IRI 
Activation of another kinase, Akt (protein kinase B), has been described 
possessing cytoprotective potential (Chan et al., 1999;Leslie et al., 2001), but 
has never been related to hepatic IRI before. Figure 51 shows a tremendous 
increase of Akt phosphorylation during reperfusion compared to preischemic 
values. 
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Figure 51: time course of Akt activation. Livers were perfused for 30 min with KH solution 
prior to ischemia (WI, 60 min, 37°C). After ischemia livers were reperfused for up to 90 min. 
Western blot analysis with antibodies against phosphorylated (phospho-Akt) and total Akt (tot-
Akt) (see “Methods”) was performed after 30 min of perfusion (Pre-I), after 60 min of WI, and 
after 45 and 90 min of reperfusion. One representative Western blot is shown. Western blots 
were analyzed densitometrically, whereby Akt phosphorylation during ischemia and reperfusion 
was expressed as x-fold of the values in the preischemic group. Values are shown as means ± 
SEM of n=3 livers in each group, analyzed in two independent Western blots. ** p<0.01 
represents significant differences of the values between preischemic and postischemic livers. 
 
4.8.1 LA preconditioning increases phosphorylation of Akt 
Akt has been described being involved in ischemic preconditioning of the rat 
heart (Tong et al., 2000) underlining the cytoprotective potential of this kinase. 
Figure 52 shows that pretreatment of livers with LA significantly increased 
activation of Akt at the end of ischemia and reperfusion.  
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Figure 52: LA preconditioning effect on Akt (protein kinase B) activation. Livers were 
perfused for 30 min in the absence (Co) or presence of 50 µM LA, which was added 20 min 
prior to ischemia (WI, 60 min, 37°C). Western blot analysis (see “Methods”) was performed 
detecting phosphorylated (phospho-Akt) and total Akt (tot-Akt) after 30 min of perfusion (Pre-I), 
after 60 min of WI, and after 45 and 90 min of reperfusion (R). One representative Western blot 
is shown for each time point. Western blots were analyzed densitometrically, whereby Akt 
phosphorylation in LA preconditioned livers is expressed as x-fold of means in the untreated 
group. Values are shown as means ± SEM of n=5 in each group, analyzed in two independent 
Western blots. *** p<0.001, * p<0.05 represent significant differences to untreated livers. 
 
4.9 Inhibition of the PI-3K/Akt pathway abrogates the 
protective effect of LA preconditioning 
In order to determine a causal relationship between Akt activation and 
hepatoprotection by LA preconditioning, livers were co-treated with LA and the 
PI-3 kinase inhibitor wortmannin (WM, 100 nM). Since Akt represents the 
downstream target of PI-3 kinase, it is well established that administration of 
WM blocks Akt activation (Gentilini et al., 2000;Chan et al., 1999;Tong et al., 
2000). LDH and PNP release were again taken as indicators for cell damage. 
Application of WM alone for 20 min prior to ischemia did not affect postischemic 
cell damage (data not shown). Figure 53 shows that LDH and PNP efflux were 
significantly reduced in LA pretreated compared to untreated livers as also seen 
in Figure 33. Importantly, simultaneous treatment with WM blocked the 
protection of LA preconditioning. These data provide evidence that LA 
preconditioning reduces IRI via the PI-3K/Akt kinase pathway. 
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Figure 53: LDH- and PNP efflux after pretreatment with LA and WM. Livers were perfused 
for 30 min in the absence (Co) or presence of 50 µM LA with or without 100 nM WM, which 
were added simultaneously 20 min prior to ischemia. After 60 min of warm ischemia (WI) livers 
were reperfused for 90 min. Analysis of lactate dehydrogenase (LDH, panel A) and purine 
nucleoside phosphorylase (PNP, panel B) activity was carried out immediately after collecting 
perfusate as described in “Methods”. Data are expressed as enzyme activity in mU x min-1 x (g 
liver)-1 weight and show means ± SEM of n=5 livers in each group. *** p<0.001, ** p<0.01, and * 
p<0.05 represent significant differences between LA treated and untreated livers. 
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4.10 LA preconditioning does not alter caspase-3-like 
activity 
Due to the fact that Akt is typically described as an antiapoptotic kinase (Chan 
et al., 1999), the impact of LA pretreatment on apoptotic processes was 
determined. Activation of the effector caspase-3 is considered essentiel for 
most apoptotic processes (Gujral et al., 2001;Cohen, 1997). Therefore, 
caspase-3-like activity is one potential target evaluating apoptotis in liver. 
In fact, elevated caspase-3-like activity after 45 and 90 min of reperfusion was 
observed. However, LA preconditioning did not significantly affect caspase-3-
like activity during reperfusion (see Figure 54). 
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Figure 54: caspase-3-like activities during reperfusion in LA preconditioned livers. Livers 
were untreated (Co) or preconditioned with 50 µM LA. 60 min of warm ischemia (WI) were 
followed by reperfusion (R) for up to 90 min. Caspase-3-like activity was determined as 
described in “Methods”. Data are expressed as x-fold caspase-3-like activity of untreated livers 
after 60 min of WI and show means ± SEM of n=5 experiments. n.s. expresses no statistical 
significance between untreated and LA pretreated livers. 
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5. RAW 264.7 murine macrophages 
The data shown so far provide mechanisms of LA action in IRI up to 90 min of 
reperfusion. However, there is overwhelming evidence that IRI continues, with 
Kupffer cells and neutrophils as the main sources for a proinflammatory 
response (Fan et al., 1999). In this context, activated KC produce a huge 
amount of NO by iNOS induced after NF-κB activation during reperfusion (Hur 
et al., 1999;Tsoulfas and Geller, 2001;Kiemer A.K., 2002).  
As the inhibition of NF-κB at the end of reperfusion (see D.4.5) suggested an 
influence of LA also on later IRI events, such as inhibition of iNOS induction, a 
murine macrophage cell culture model (RAW 264.7) was chosen to get first 
hints on this hypothesis. The applied IRI model was unsuitable to determine late 
reperfusion events (>5 h) as already mentioned in the introduction (see B.2.1.5).  
KC belonging to the mononuclear phagocyte system of the liver share many 
functions with macrophages. Upon inflammatory stimuli, such as 
lipopolysaccharide (LPS), KC as well as macrophages trigger signals for the 
production of a variety of bioactive substances. Both cell types lead to an 
increased NO production via activation of NF-κB coupled to the induction of 
iNOS after LPS treatment (Kiemer A.K., 2002). Therefore, RAW macrophages 
were used as a model to obtain first informations about the potential of LA to 
influence KC activation. 
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5.1 Inhibition of LPS-induced nitrite accumulation by 
LA 
RAW 264.7 macrophages were stimulated with LPS (1 µg/ml) for 20 h to evoke 
iNOS induction. Co-treatment of cells with LA significantly reduced nitrite 
accumulation in doses ≥ 5 µg/ml in RAW 264.7 macrophages (Figure 55). 
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Figure 55: dose dependent inhibition of LPS-induced nitrite production in RAW 264.7 by 
LA. RAW 264.7 macrophages were cultured for 20 h in either medium alone or in medium 
containing LPS (1 µg/ml) in the absence or presence of LA (5-500 µg/ml). Nitrite accumulation 
was determined as described in “Methods“. Data are expressed as percentage of nitrite 
accumulation in cells activated with 1 µg/ml LPS (100%) and show means ± SEM. of one or two 
independent experiments performed in triplicates. *** p<0.001 and * p<0.05 represent significant 
differences compared to the values in LPS activated cells. 
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5.2 Interaction of LA with NO produced in situ 
In order to determine whether reduced nitrite concentrations in supernatants of 
LA treated cells were due to a direct reaction of LA with NO due to the radical 
scavenging properties of LA (Biewenga et al., 1997;Biewenga and Bast, 
1995;Packer et al., 1997;Packer et al., 1995) the following experiment was 
performed: The NO donor sodium nitroprusside (SNP) was added to the cells 
simultaneously with LA and nitrite accumulation was determined after 1.5, 2.5, 
and 4.5 h. These experimental conditions showed a slightly but significantly 
reduced nitrite concentration in the presence of LA after 1.5 h (Figure 56). LA 
did not have any influence on nitrite formation at later time points. These data 
suggest that LA to a certain extent directly interacts with NO and thereby 
inhibits nitrite formation. 
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Figure 56: nitrite accumulation after administration of NO donor. RAW 264.7 macrophages 
were either left untreated or treated with the NO donor SNP (1 mg/ml) in the presence or 
absence of LA (20 µg/ml). Nitrite accumulation was assessed as described under “Methods”. 
Data are expressed as percentage of nitrite accumulation in cells activated with SNP (100%) 
and show means ± SEM. of two to four independent experiments performed in triplicates. *** 
p<0.001 represents significant differences compared to the values in cells treated with SNP for 
1.5 h. 
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5.3 Cell viability 
The inhibitory effect of LA on NO synthesis was not due to cytotoxicity of LA in 
concentrations up to 500 µg/ml. As an indicator of cell viability, the 
mitochondrial respiratory activity of the cells was assessed. In RAW 264.7 
macrophages viability of cells in the presence of LPS + LA was even 
significantly higher than in cells treated with LPS only (Figure 57), therefore, a 
decrease of nitrite accumulation, because of a reduced number of viable cells 
can be excluded.  
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Figure 57: LA increased cell viability of RAW 264.7 macrophages. RAW 264.7 
macrophages were either left untreated or treated with LPS (1 µg/ml) in the absence or 
presence of LA (20-500 µg/ml). Cell viability was determined by MTT test as described in 
“Methods”. Data are expressed as means ± SEM. of one or two independent experiments 
performed in triplicates. Viability of cells treated with LPS only was referred to as 100%.            
** p<0.01 and * p<0.05 represent significant differences compared to the values in LPS 
activated cells. 
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E. Discussion 
1. Validation of the liver perfusion system 
At the beginning of this study the system of the isolated perfused rat liver had to 
be established. Control parameters of the perfusion system were the common 
features describing liver cell viability and hepatic function: enzyme release, 
portal pressure, and bile flow. 
In the literature enzyme efflux rates of approx. 2-15 mU x min-1 x (g liver)-1 for 
LDH and 0.2-5 mU x min-1 x (g liver)-1 for PNP (Bilzer M., 1997) were proposed 
and were perfectly in line with the values seen in the used perfusion system 
(see Figure 26). Data provided for portal pressure were also in agreement with 
previous reports, which describe values between 3-6 cm water (Dahl S., 
1997;Bilzer M., 1997) for continuously perfused rat liver (see Figure 27). 
Concerning bile flow, Dahl and colleagues stated a decrease in isolated 
perfused rat livers from approx. 1.3 - 0.8 µl x min-1 x (g liver)-1 within 2 h of 
perfusion (Dahl S., 1997;Gores et al., 1986) reflecting the values obtained in 
this work (see Figure 28). On the basis of these results the perfusion system 
was considered as valid to perform further experiments. 
The next step was to elucidate, whether administration of LA does affect the 
parameters used. Due to the fact that no information was available about LA in 
hepatic IRI so far and only little has been published about its use in the isolated 
perfused rat liver (Spence and McCormick, 1976;Peinado et al., 1989), it was 
necessary to initially determine whether administration of LA influences the 
applied system. Performing continuous perfusions (D.1.1) showed that LA did 
not significantly alter enzyme release and portal pressure, indicating that LA 
administration did not influence liver cell viability and hepatic circulation in the 
perfusion system. A novel finding represents the obtained increase of bile flow 
in LA treated livers. LA has been described before to enter bile in rat liver 
perfusion (Borbe H.O. and Ulrich H., 1989), but not to enhance bile formation. 
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2. Short time infusion of H2O2 
The fact that Kupffer cell activation during reperfusion leads to an increased 
sinusoidal ROS formation, a further preliminary set of experiments was done 
mimicking ROS production by infusing H2O2. H2O2 as a reactive oxygen 
intermediate was chosen for these experiments, because it is proven to be 
involved in ROS-induced hepatic IRI (Jaeschke et al., 1991;Bilzer M., 1997). 
The experiments should clarify the question, whether LA is able to attenuate 
H2O2-induced liver cell injury. However, LA did not show any protection in H2O2-
induced injury. Portal pressure in the LA treated groups even showed a 
significant increase after H2O2 application. This surprising result might be 
explained by the generation of a LA oxidation product having vasoconstrictive 
properties.  
3. LA attenuates IRI of the rat liver 
The main part of this study investigated the influence of LA on ischemia 
reperfusion injury (IRI) of the rat liver. Basis for choosing LA as a possible 
substance attenuating IRI was derived from its very promising pharmacological 
profile described in the introduction (see B.3). Among the properties of LA 
mentioned there, especially interesting concerning IRI are: the antioxidative 
potential of LA and its metabolites (B.3.5.1), the influence on energy 
metabolism (B.3.5.4), and very recently the findings of Konrad et al. (Konrad et 
al., 2001) suggesting that LA specifically activates molecular signalling 
cascades of the cell (B.3.4). Additionally, LA is widely used in the therapy of 
diabetic disorders and is therefore documented in numerous clinical trials to be 
well tolerated (see B.3.4) (Coleman Michael D., 2001). 
3.1 LA protects from IRI 
This work shows for the first time that this established antidiabetic agent 
(Ziegler et al., 1999) attenuates hepatic IRI. Pre- as well as postischemic, and 
continuous administration of LA were shown to reduce IRI. Focussing on the 
preconditioning effect of LA it was also shown for the first time that the survival 
kinase Akt is involved in protection from IRI of the rat liver. This assumption is 
based on two findings. First, LA increased phosphorylation of Akt and second, 
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most importantly the PI-3 kinase inhibitor wortmannin abrogated the protective 
effect of LA preconditioning.  
Furthermore, additional effects of LA were observed, which should also be 
discussed in terms of its beneficial role in attenuating IRI.  
3.2 Raised ATP availability 
Preconditioning with LA lead to an increased ATP content in liver tissue during 
ischemia and reperfusion. The potency of LA to increase ATP levels has been 
reported before in rat heart mitochondria (Zimmer et al., 1995) and diabetic 
hearts (Strodter et al., 1995). Since ATP depletion occuring during ischemia 
(Jaeschke et al., 1988;Gerbes et al., 1998) leads to liver cell damage, the 
increased energy pool after LA pretreatment might contribute to the protective 
effect (Figure 48). 
3.3 Inhibition of NF-κB and AP-1 activation 
LA preconditioning also inhibited the activation of two pivotal redox-sensitive 
transcription factors, namely nuclear factor κB (NF-κB) and activator protein 1 
(AP-1). LA has been previously reported to inhibit NF-κB binding activity in 
various cell culture models, supporting these data (Suzuki et al., 1995). 
Activation of transcription factors, such as NF-κB and AP-1, has been linked to 
the pathophysiology of IRI by activating inflammatory cascades leading to organ 
damage (Ricciardi et al., 2000;Banafsche et al., 2001;Fan et al., 1999;Zwacka 
et al., 1998;Yamada et al., 2000). Thus, inhibition of these proinflammatory 
mediators might contribute to a protective effect. However, in this study LA 
attenuated the transcription factors mainly at late reperfusion time points (Figure 
47). Therefore, these mechanisms seem most likely not to be essential for the 
protective effect of LA, which is seen already at the beginning of the reperfusion 
period. For later IRI events, such as iNOS-induction after NF-κB activation, cell 
culture experiments should give further hints on LA influencing NF-κB target 
gene expression (D.5). 
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3.4 Postischemic LA application 
The inhibitory effect of LA on the activition of the redox-regulated transcription 
factors NF-κB and AP-1 might be linked to a reduced ROS production during 
IRI. These direct antioxidative properties of LA are most likely responsible for 
the protection conveyed by postischemic application of LA. The fact that ROS 
production is highly increased during early reperfusion (Bilzer and Gerbes, 
2000;Rauen et al., 1994) might explain why application of potent antioxidants 
during reperfusion protects from IRI (Bilzer et al., 1999). This hypothesis is 
supported by demonstrating an immense difference of LA- and TNLA-amounts 
in perfusate between pre- and postischemically administered LA (Figure 42), 
which represents a high sinusoidal antioxidative potential for postischemic 
treatment. Therefore, protection by postischemic administration might be due to 
the direct ROS scavenging properties of LA. In addition, data from the H2O2-
experiments (see D.2) suggest that application of LA seems not to be involved 
in attenuating the H2O2-induced part of liver cell damage during IRI. 
3.5 Influence on thiol/disulfide status 
Besides such a direct interaction with ROS, antioxidant properties might also 
arise from the modulation of other redox dependent factors, such as GSH. In 
fact, LA increases GSH levels in various systems by improving cystine 
utilization (Han et al., 1997). However, in this study an enhanced cysteine or 
GSH contents in liver or perfusate after applying LA could not be shown (see 
Figure 43, Figure 45) and therefore an indirect antioxidative action via GSH as 
hypothesized could be excluded. Pretreatment of livers with LA rather reduced 
than augmented hepatic GSH content (Figure 45). Interestingly, GSH depletion 
has been reported before to be hepatoprotective after different stimuli (Hentze 
et al., 2000). The reduced contents of CYSSX in perfusate of LA pretreated 
livers might be expression of a reduced sinusoidal ROS formation during 
reperfusion of these livers (Figure 44). 
3.6 Activation of kinases 
The most meaningful effect of LA in this work surely is the increased Akt 
activation observed in LA preconditioned organs. Akt has been reported to 
possess cytoprotective potential as has also been described for p38 MAPK. 
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Interestingly, LA did not activate p38 MAPK in our model of IRI (Figure 50), 
although LA has previously been shown to activate p38 MAPK in muscle cells 
(Konrad et al., 2001). Thus, LA does not confer its protection via this kinase 
which is known to mediate ischemic preconditioning of hearts (Weinbrenner et 
al., 1997) as well as in hypoxic preconditioning of hepatocytes (Carini et al., 
2001). 
Up to now, no information is available on a potential cytoprotective action of Akt 
in hepatic IRI. Only one work describes a role for Akt in ischemic 
preconditioning of rat hearts (Tong et al., 2000). LA has been reported to 
activate Akt, an effect which was connected to its antihyperglycemic activity 
(Konrad et al., 2001;Yaworsky et al., 2000). This work here reports for the first 
time that activation of this survival kinase, as induced by LA pretreatment, is 
causally involved in attenuating hepatic IRI, since inhibition of PI-3 kinase by 
wortmannin abrogated the protective effect of LA (Figure 53). Therefore, LA-
induced activation of Akt is pivotal for LA-mediated hepatoprotection. Anyway, 
as suggested by the time course of Akt, the tremendous postischemic activation 
of this survival kinase also in untreated livers might represent a key event of 
hepatic cells resisting cell death (Figure 51). The observation of an additionally 
increased Akt activation by LA pretreatment at the end of reperfusion might also 
demonstrate a forced stress resistance in these livers (Figure 52). 
3.7 No influence on apoptotic cell death 
The cytoprotective effect of Akt has been mainly attributed to its antiapoptotic 
potential so far (Chan et al., 1999). However, hepatoprotection by LA does not 
seem to be involved in antiapoptotic processes of our model of IRI. The 
postischemic activation of caspase-3-like activity proposes an involvement of 
apoptotic cell death during IRI, but LA application did not influence these 
processes since caspase activities remained unaltered (Figure 54).  
Therefore, this observation suggests that Akt activation might not only attenuate 
apoptotic processes but also protect from necrotic cell death, as recently also 
reported by Jin et al. in neuronal cells (Jin et al., 2000). 
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4. Inhibition of NO production in RAW 264.7 
macrophages by LA 
Especially the reduced activation of NF-κB at the end of reperfusion (see D.4.5) 
suggested that LA is able to also influence later IRI events. Due to the fact that 
the isolated perfused rat liver is only suitable for perfusion times up to 5 h, a 
change of the experimental model was necessary to get first insights in possible 
later mechanisms. For this purpose, a RAW 264.7 macrophage model was 
used (see also D.5) to evaluate the influence of LA on NF-κB target gene 
expression. As a later reperfusion event, NO formation after NF-κB activation 
and subsequent iNOS induction has been described (Tsoulfas and Geller, 
2001). The fact that iNOS knockout mice showed reduced liver cell damage 
after warm ischemia and reperfusion suggests that NO production is harmful to 
the reperfused liver (Lee et al., 2001). Data provided in the present study, using 
RAW macrophages, gave first hints about the potency of LA to reduce NO 
formation (see Figure 55). A distinct effect of LA could be shown regarding 
iNOS induction by LPS, whereas LA treatment in concentrations > 200 µg/ml 
completely inhibited nitrite formation. Experiments with the NO donor sodium 
nitroprusside showed that a decreased NO formation might be partly explained 
by a NO scavenging effect of LA (Figure 56). However, this effect seems not to 
be strong enough to explain the complete inhibition of NO production after LPS 
stimulation. In conclusion, the macrophage experiments provide evidence for a 
role of LA to attenuate expression of NF-κB target genes (e.g. iNOS), which are 
discussed to aggravate IRI. 
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Figure 58: shown protective mechanisms of LA in hepatic IRI. Kupffer cell (KC), endothelial 
cell (EC),  granulocyte (GC), reactive oxygen species (ROS),  nitric oxide (NO). 
 
To summarize, this work shows for the first time that LA reduces IRI of the rat 
liver. Thus, LA treatment might represent a new pharmacological approach in 
attenuating hepatic IRI. Even more importantly, it is shown that preconditioning 
with LA is mediated via the PI-3K/Akt pathway. Therefore, these data reveal 
activation of Akt as a new target mediating protection from hepatic IRI. 
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F. Summary 
Ischemia reperfusion injury (IRI) represents a major clinical problem in liver 
transplantation and resection. Main pathophysiological events during this injury 
comprise depletion of ATP, Kupffer cell activation with subsequent formation of 
reactive oxygen species and inflammatory response. Depending on the severity 
of IRI, cell damage leads to necrotic or apoptotic liver cell death, resulting in 
organ dys- or even nonfunction.  
The present work investigated the potential of α-lipoic acid (LA), a well 
established agent in the therapy of diabetic polyneuropathy, to reduce IRI of the 
rat liver. In the system of the isolated perfused rat liver, an experimental model 
of hepatic IRI, LA was utilized in different treatment protocols and 
concentrations.  
As a key result of this study, pre- as well as postischemic treatment with LA was 
shown for the first time to markedly reduce hepatic IRI.  
Further investigations characterized the underlying mechanisms of LA action, 
focussing on the preconditioning protocol. Thereby, LA was shown to increase 
hepatic ATP content during ischemia and reperfusion, suggesting a better 
energy availability in these organs. Activation of the redox-sensitive 
transcription factors NF-κB and AP-1 was reduced by LA, suggesting a 
decreased inflammatory response of the liver.  
Most importantly, this work describes for the first time that the protein kinase Akt 
plays a crucial role in IRI. The cytoprotective kinase was activated by LA 
preconditioning during ischemia and reperfusion. Blocking Akt activation by 
simultaneous application of wortmannin, a selective PI-3 kinase inhibitor, 
abrogated the LA preconditioning effect, showing a causal involvement of Akt in 
LA-mediated protection from IRI. Therefore, Akt activation can be regarded as a 
new protective mechanism in hepatic IRI. 
 
To conclude, LA treatment might represent a new pharmacological approach in 
attenuating IRI of the liver.  
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G. Appendix 
1. Abbreviations 
A Ampere 
APS Ammonium persulfate 
ATP Adenosine-5’-triphosphate 
BSA Bovine serum albumine 
C Celsius 
CCl4 Carbon tetrachloride 
Co control 
CoA Coenzyme A 
cpm Counts per minute 
CYS Cysteine 
CYSSX Oxidized cysteine 
dist. Distilled 
DMEM Dulbecco’s Modified Essential Medium 
DMSO Dimethylsufoxide 
DNA Deoxyribonucleic acid 
DTE Dithioerythritol 
DTT Dithiothreitol 
EDTA Ethylene diamine tetraacetic acid 
EGTA Ethylene glycol-bis(aminoethylether) tetraacetic acid 
EMSA Electrophoretic mobility shift assay 
FCS Fetal Calf Serum 
g gram 
g Acceleration due to gravity 
G-6-P-DH Glucose-6-phosphate-dehydrogenase 
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GSH  Glutathione 
GSSX Oxidized glutathione 
h Hour 
HEPES N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid 
HK Hexokinase 
HPLC High performance liquid chromatography 
HRP Horseradish peroxidase 
i.v. intravenous 
iNOS Inducible nitric oxide synthase 
IRI Ischemia reperfusion injury 
KC Kupffer cell 
L Liter 
LA Racemic α-lipoic acid 
LDH Lactate dehydrogenase 
LPS Lipopolysaccharide 
m Milli 
M Molar 
MEK MAP/ERK kinase 
mg milligram 
min Minute 
MTT 3-(4, 5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
NADH Dihydronicotinamide adenine dinucleotide 
NADH-Na2 Dihydronicotinamide adenine dinucleotitide disodium salt 
NEM N-ethylmaleimide 
Nonidet Non-ionic detergent 
p.o. Peroral 
PAA Polyacrylamide 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
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PI-3K Phosphatidylinositol-3-kinase 
PMSF Phenylmethylsulfonyl fluoride 
PNP Purine nucleoside phosphorylase 
Pre-I Pre-ischemia 
PVDF Polyvinylidenfluoride 
R Reperfusion 
ROS Reactive oxygen species 
RT Room temperature 
SDS Sodium dodecyl sulfate 
sec second 
SEM Standard error of mean 
SNP Sodium nitroprusside 
STE Sodiumchloride/tris-HCl/EDTA 
TBE Tris, borate, EDTA buffer 
TBS-T Phosphate buffered saline solution with Tween 
TEA Triethanolamine 
TEMED N,N,N’,N’-tetramethylethylenediamine 
TNF-α Tumor necrosis factor α 
TNLA Tetranorlipoic acid 
TPP Thiamine pyrophosphate 
Tris Tris(hydroxymethyl)-aminomethane 
U Unit 
V Volt 
% (m/v) Mass per volume per cent 
% (v/v) Volume per cent 
µ Micro 
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